Document:

EX-10.21

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with the
Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 Exhibit 10.21

 DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT 

THIS DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT is made and entered into as of January 17, 2007 (the “Effective
Date”) by and between Portola Pharmaceuticals, Inc., a Delaware corporation, having a principal place of business at 270 East Grand Avenue, Suite 22, South San Francisco, California 94080 (Telephone: 650-246-7300, Facsimile: 650-246-7776)
(“Portola”) and Hovione Inter Limited, a Swiss company having its principal place of business at Bahnhofstrasse 21 CH-6000 Lucerne 7 Switzerland, (“Hovione,” together with its Affiliates
“Manufacturer”). 
 RECITALS: 
 WHEREAS, Portola desires to engage Manufacturer to perform certain Services (as defined below), on the terms and conditions set forth below, and Manufacturer desires to perform such Services for Portola.

 AGREEMENT: 
 NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants of the parties set forth in this Agreement, the parties hereto agree as follows: 

1. Definitions. Unless this Agreement expressly provides to the contrary, the following terms, whether used in the singular or
plural, have the respective meanings set forth below: 
 1.1 “Affiliate” means, with respect to a party, any
person or entity which controls, is controlled by or is under common control with such party. As used in this Agreement, “control” means (a) in the case of corporate entities, direct or indirect ownership of at least fifty percent
(50%) of the stock or shares having the right to vote for the election of directors, and (b) in the case of non corporate entities, the direct or indirect power to manage, direct or cause the direction of the management and policies of the
non corporate entity or the power to elect at least fifty percent (50%) of the members of the governing body of such non-corporate entity. 
 1.2 “Agreement” means this Development and Manufacturing Services Agreement, together with all Appendices attached hereto, as amended from time to time by the parties in accordance with
Section 15.6, and all fully signed Work Orders entered into by the parties. 
 1.3 “API/Drug Substance”
means the active pharmaceutical ingredient identified on the applicable Work Order. 
 1.4 “API Starting
Material” means a raw material that is used in the production of an API and that is incorporated as a significant structural fragment in to the structure of the API. API starting material are normally commercially available and of defined
chemical and physical properties and structure. 

 1.5 “Applicable Law” means all applicable ordinances, rules, regulations,
laws, guidelines, guidances, requirements and court orders of any Authority, as amended from time to time. 
 1.6
“Authority” means any government regulatory authority responsible for granting approvals (e.g. New Drug Application approvals) for the performance of Services under this Agreement including, without limitation, the FDA, if
applicable. 
 1.7 “Batch” means a specific quantity of Product that is intended to be of uniform character and
quality, within specified limits, and is produced during the same cycle of Manufacture as defined by the applicable Batch Documentation. 
 1.8 “Batch Documentation” has the meaning set forth in Section 6.2. 
 1.9 “Certificate of Analysis” means a document, signed by an authorized representative of Manufacturer, describing Specifications for, and testing methods applied to, Product, and the
results thereof. 
 1.10 “Certificate of Compliance” means a statement signed by an authorized representative of
Manufacturer, attesting that the Product was manufactured in accordance with applicable cGMP. 
 1.11 “cGMP”
means the current good manufacturing practice regulations applicable to the Manufacture of Product as defined by the Q7A Guidance on Good Manufacturing Practices of the International Conference on Harmonization of Technical Requirements of
Pharmaceuticals for Human Use (ICH Q7A). 
 1.12 “Change Order” has the meaning set forth in Section 5.3.

 1.13 “Confidential Information” has the meaning set forth in Section 10. 

1.14 “Deliverables” means the reports and other tangible items (other than Product) to be prepared, obtained, generated
or derived by Manufacturer as part of the Services and to be delivered to Portola, as specified in the relevant Work Order and this Agreement. 
 1.15 “Develop” or “Development” means the studies and other activities conducted by Manufacturer under this Agreement to develop all or any part of a Manufacturing
Process. 
 1.16 “Duly Authorized Representative” means an employee of, or consultant to, Portola who is aware
of the requirements of this Agreement and bound by a written confidentiality agreement no less strict than the obligations of Portola as set forth in this Agreement. 
 1.17 “Equipment” means any equipment or machinery, including Portola Equipment, used by Manufacturer in the Development and/or Manufacturing of Product, or the holding, processing,
testing, or release of Product. 

  
 [*] = Certain
confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 2 

 1.18 “Facility” means the facilities of Manufacturer identified in the
applicable Work Order. 
 1.19 “FDA” means the United States Food and Drug Administration, and any successor
agency having substantially the same functions. 
 1.20 “FDCA” means the United States Federal Food, Drug and
Cosmetic Act, 21 U.S.C. §321 et seq., as amended from time to time. 
 1.21 “force majeure” has the
meaning set forth in Section 15.2. 
 1.22 “Improvements” means all Technology (whether or not protectable
under patent, trademark, copyright or similar laws) that is conceived or reduced to practice by either party or jointly by the parties in the performance of Services and that relates solely to the Portola Technology. 

1.23 “IND” means an Investigational New Drug application filed with the FDA in accordance with Applicable Law.

 1.24 “Intermediate” means a material produced during steps of the processing of an API that undergoes further
molecular change or purification before it becomes an API. 
 1.25 “Manufacture” and
“Manufacturing” means any steps, processes and activities the Manufacturer takes to produce Product, including without limitation, the manufacturing, processing, packaging, labeling, quality control testing, release, storage or
supply of Product. 
 1.26 “Manufacturer Indemnitee” has the meaning set forth in Section 12.2.

 1.27 “Manufacturer Technology” means any Technology (a) owned or otherwise controlled by Manufacturer
prior to the Effective Date, (b) developed or obtained by or on behalf of Manufacturer independent of this Agreement and without reliance upon Confidential Information of Portola or Portola Technology or (c) developed or obtained by or on
behalf of Manufacturer and that relates solely to Manufacturer’s general manufacturing processes and/or platform Technology that are not specific to the Product or to Portola Materials. 

1.28 “Manufacturing Process” means any and all processes (or any step in any process) used or planned to be used by
Manufacturer to Manufacture Product, as evidenced in the Batch Documentation. 
 1.29 “Portola Indemnitee” has
the meaning set forth in Section 12.1. 
 1.30 “Portola Materials” means the materials identified in the
applicable Work Order and provided by Portola including labels (if any) for Product. 
 1.31 “Portola
Technology” means any Technology, other than Manufacturer Technology and Improvements, that relates to Portola Materials and/or the Product and (a) is owned or otherwise controlled by Portola prior to the Effective Date or (b) is
developed or obtained by or on behalf of Portola independent of this Agreement and without reliance upon the Confidential Information of Manufacturer or Manufacturer Technology. 

  
 [*] = Certain
confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 3 

 1.32 “Product” means any Regulated Intermediate, API/Drug Substance
manufactured by the Manufacturer as specified in the applicable Work Order. 
 1.33 “Project Manager” has the
meaning set forth in Section 3.1. 
 1.34 “Quality Agreement” has the meaning set forth in
Section 2.2. 
 1.35 “Quality Representative” shall mean a representative from each Party primarily responsible
for the quality assurance (“QA”) or quality control (“QC”) of Services and Product and identified in Attachment 1 to the Quality Agreement. Such Quality Representatives may be changed at any time with written notice provided to
the other Party. 
 1.36 “Raw Material” is a general term used to denote starting materials, reagents, and
solvents intended for use in the production of Intermediates, Regulated Intermediates or Product. 
 1.37
“Records” has the meaning set forth in Section 5.4(a). 
 1.38 “Regulated Intermediate” means an
isolated intermediate that is produced during the manufacture of API/Drug Substance under cGMP. 
 1.39
“Reprocess” and “Reprocessing” means introducing a Product back into the process and repeating appropriate manipulation steps that are part of the established Manufacturing Process. Continuation of a process step
after an in-process control test shows the process to be incomplete is not considered reprocessing. 
 1.40
“Rework” and “Reworking” means subjecting a Product to one or more processing steps that are different from the established Manufacturing Process. 

1.41 “Services” means the Development, Manufacturing and/or other services described in a Work Order entered into by the
parties. 
 1.42 “Specifications” means the list of tests, references to any analytical procedures and
appropriate acceptance criteria which are numerical limits, ranges or other quantitative criteria for tests described in order to establish a set of criteria to which Product at any stage of Manufacture should conform to be considered acceptable for
its intended use that are provided by or approved by Portola and set forth in a Work Order, as such specifications are amended or supplemented from time to time by Portola in writing and set forth in a Work Order and in accordance with
Section 5.3. 
 1.43 “Technology” means all methods, techniques, trade secrets, copyrights, know-how,
data, documentation, regulatory submissions, specifications and other intellectual property of any kind (whether or not protectable under patent, trademark, copyright or similar laws) 

  
 [*] = Certain
confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 4 

 1.44 “Work Order” means a written work order, substantially in the form
attached hereto as Appendix A, for the performance of Services by Manufacturer under this Agreement. 
 2. Engagement of
Manufacturer. 
 2.1 Services and Work Orders. From time to time, Portola may wish to engage Manufacturer to perform
Services for Portola. Such Services will be set forth in a Work Order. Each Work Order will be appended to this Agreement and will set forth the material terms for the project, and may include the scope of work, specified Services, Specifications,
Deliverables, timelines, milestones (if any), quantity, budget, payment schedule and such other details and special arrangements as are agreed to by the parties with respect to the activities to be performed under such Work Order. No Work Order will
be effective unless and until it has been agreed to and signed by authorized representatives of both parties. Documents relating to the relevant project, including without limitation Specifications, proposals, quotations and any other relevant
documentation, will be attachments to the applicable Work Order and incorporated in the Work Order by reference. Each fully signed Work Order will be subject to the terms of this Agreement and will be incorporated herein and form part of this
Agreement. Manufacturer will perform the Services specified in each fully signed Work Order, as amended by any applicable Change Order(s), and in accordance with the terms and conditions of such Work Order and this Agreement. Notwithstanding the
foregoing, nothing in this Agreement will obligate either party to enter into any Work Order under this Agreement. 
 2.2
Quality Agreement. The parties will also agree upon a Quality Agreement containing quality assurance provisions for the Manufacture of Product (“Quality Agreement”), which agreement will be attached to the applicable Work
Order and incorporated by reference in the Work Order. 
 2.3 Conflict Between Documents. If there is any conflict,
discrepancy, or inconsistency between the terms of this Agreement and any Work Order, Quality Agreement, purchase order, or other form used by the parties, the terms of this Agreement will control. 

3. Project Performance. 
 3.1 Project Manager. Each party will appoint a project manager having primary responsibility for day-to-day interactions with the other party for the Services (each, a “Project Manager”),
who will be identified in the applicable Work Order. Each party may change its Project Manager by providing written notice to the other party in accordance with Section 15.3; provided that Manufacturer will use reasonable efforts to provide
Portola with at least forty-five (45) days prior written notice of any change in its Project Manager for the Services. Except for notices or communications required or permitted under this Agreement, which will be subject to Section 15.3,
or unless otherwise mutually agreed by the parties in writing, all communications between Manufacturer and Portola regarding the conduct of the Services pursuant to such Work Order will be addressed to or routed directly through the parties’
respective Project Manager. 

  
 [*] = Certain
confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 5 

 3.2 Communications. The parties will hold project team meetings via teleconference or
in person, on a periodic basis as agreed upon by the Project Managers. Manufacturer will provide written reports to Portola as specified in the applicable Work Order. 
 3.3 Subcontracting. Manufacturer may not subcontract with any subcontractor to perform any of its obligations under this Agreement without the prior written consent of Portola, which shall not be
unreasonably withheld or delayed; provided, that, notwithstanding the foregoing, Manufacturer may subcontract certain non-essential or routine tasks without Portola’s consent, provided that they are tasks which would normally be subcontracted
by Manufacturer in the normal course of its business (e.g., cleaning of cGMP suites, and maintenance and service of Facility systems) and are not tasks that relate specifically to the Manufacture or storage of Product under this Agreement.
Manufacturer will be solely responsible for the performance of any permitted subcontractor, and for costs, expenses, damages, or losses of any nature arising out of such performance as if such performance had been provided by Manufacturer itself
under this Agreement. Manufacturer will cause any such permitted subcontractor to be bound by, and to comply with, provisions that are comparable in scope to the terms of this Agreement, as applicable, including without limitation, all
confidentiality, quality assurance, regulatory and other obligations and requirements of Manufacturer set forth in this Agreement. 
 3.4 Duty to Notify. If Manufacturer, at any time during the term of this Agreement, has reason to believe that it will be unable to perform or complete the Services, Manufacturer will promptly
notify Portola thereof. Compliance by Manufacturer with this Section 3.4 will not relieve Manufacturer of any other obligation or liability under this Agreement. 
 4. Materials. 
 4.1 Supply of Materials. Unless the parties
otherwise agree in a Work Order, Manufacturer will supply, in accordance with the relevant raw material specifications set forth in the applicable Work Order, all materials to be used by Manufacturer in the performance of Services under such Work
Order other than the Portola Materials specified in such Work Order. Portola or its designees will timely provide Manufacturer with the Portola Materials. Manufacturer agrees (a) to promptly provide Portola with written notice of receipt of all
such Portola Materials, (b) not to provide Portola Materials to any third party without the prior written consent of Portola, (c) not to use Portola Materials for any purpose other than conducting the Services, including, without
limitation, not to analyze, characterize, modify or reverse engineer any Portola Materials or take any action to determine the structure or composition of any Portola Materials unless required pursuant to a Work Order, and (d) to destroy or
return to Portola at Portola’s cost all unused quantities of Portola Materials according to Portola’s written directions. 
 4.2 Ownership of Materials. Manufacturer shall not acquire any title to and/or ownership of the Portola Materials as a result of the supply of such Portola Materials by Portola pursuant to this
Agreement. Manufacturer will provide within the Facility an area or areas where the Portola Materials, Product, and any intermediates (and components) of Product specified in any Work Order are reasonably segregated, labeled and stored in accordance
with the Specifications and the Quality Agreement and in such a way as to be able at all times to clearly 

  
 [*] = Certain
confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 6 

 
distinguish such materials from other products and materials belonging to Manufacturer or held by it for a third party’s account. Manufacturer will at all times take commercially reasonable
measures to protect the Portola Materials, Product, any intermediates (and components) of Product specified in any Work Order risk of loss or damage at all stages of the Manufacturing Process. Manufacturer will ensure that Product will not be
subject to any liens or encumbrances at the time of delivery to Portola as a result of the acts or omissions of Manufacturer or its Affiliates. Manufacturer will promptly notify Portola if at any time it believes any Product or Portola Materials
have been damaged, lost or stolen. The value of Portola Materials shall be [*] which is [*] or [*] of [*]. 
 5. Development
and Manufacture of Product. 
 5.1 Resources; Applicable Law. Manufacturer will comply with all Applicable Law in
performing Services. 
 5.2 Facility. 
 (a) Manufacturer will perform all Services at the Facility, provide all staff necessary to perform the Services in accordance with the terms of the applicable Work Order and this Agreement, and hold at
such Facility all Equipment, Portola Materials and other items used in the Services. Manufacturer will not change the location of such Facility or use any additional facility for the performance of Services under this Agreement without providing
Portola with at least [*] prior written notice to, and prior written consent from, Portola, which consent will not be unreasonably withheld or delayed (it being understood and agreed that Portola may withhold consent pending satisfactory completion
of a quality assurance audit and/or regulatory impact assessment of the new location or additional facility, as the case may be). Manufacturer will maintain, at its own expense, the Facility and all Equipment required for the Manufacture of Product
in a state of repair and operating efficiency consistent with the requirements of the Quality Agreement and all Applicable Law. 
 (b) Licenses and Permits. Manufacturer will be responsible for obtaining, at its expense, any Facility or other licenses or permits, and any regulatory and government approvals necessary for the
performance of Services by Manufacturer under this Agreement. At Portola’s reasonable request, Manufacturer will provide Portola with copies of all such approvals and submissions to Authorities, and Portola will have the right to reference any
and all such approvals or submissions in connection with any or all applications submitted to any Authority with respect to the regulatory approval and/or commercial development of Product. 

5.3 Access to Facility. Manufacturer agrees that upon not less than [*] prior written notice and no more than [*] per calendar
year, excluding technical visits or for-cause audits, to have up to [*] Portola employees or its Duly Authorized Representatives visit during normal business hours and during active Manufacturing, to audit the Facility and Manufacturing Process to
ascertain compliance by Manufacturer with the terms of this Agreement, including, without limitation, inspection of (i) the Equipment and materials used in the performance of Services, (ii) the holding facilities for such materials and
Equipment, and (iii) all Records relating to such Services and the Facility. Portola will also have the right, at its expense and by 

  
 [*] = Certain
confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 7 

 
providing at least [*] prior written notice, to conduct “mock” pre-approval audits during normal business hours, and Manufacturer agrees to reasonably cooperate with Portola in such
“mock audits.” Portola and its Duly Authorized Representatives who audit Manufacturer’s Facility and Records shall at all times comply with Manufacturer’s rules, regulations and SOPs relating to inspections and visits to the
Facility, and Portola retains full responsibility and liability for the presence and actions of its Duly Authorized Representatives while on Manufacturer’s premises. Any information disclosed in writing, orally or by inspection of tangible
objects shall be considered Confidential Information of Manufacturer and shall be subject to Section 10 of this Agreement. Fees for additional audits that occur more than [*] per year calendar year will be charged at current rates. Changes
to Work Orders, Delays, Manufacturing Process and Specifications. 
 (a) Changes to Work Orders. If the scope of
work of a Work Order changes, then the applicable Work Order may be amended as provided in this Section 5.3(a). If a required modification to a Work Order is identified by Portola, or by Manufacturer, the identifying party will notify the other
party in writing as soon as reasonably possible. In either case, Manufacturer will provide Portola with a change order containing a description of the required modifications and their effect on the scope, fees and timelines specified in the Work
Order (“Change Order”) and will use reasonable efforts to do so within ten (10) business days of receiving or providing such notice, as the case may be. No Change Order will be effective unless and until it has been signed by
authorized representatives of both parties. If Portola approves any such Change Order, Portola will be responsible for the payment of any fee increase referenced in such Change Order. If Portola does not approve such Change Order, and has not
terminated the Work Order, but requests the Work Order to be amended to take into account the modification, then the parties will use reasonable efforts to agree on a Change Order that is mutually acceptable. If practicable, Manufacturer will
continue to work on the existing Work Order during any such negotiations, provided the parties agree that such efforts would facilitate the completion of the work envisioned in the proposed Change Order, but will not commence work in accordance with
the Change Order until it is authorized in writing by the authorized representatives of both parties. 
 (b) Delays. If
delays occur in performance of the Services under a Work Order related to Portola’s failure to timely supply Manufacturer with Portola Materials, Portola Technology or information required to perform such Services, Manufacturer shall be
entitled, at its sole option, to (1) reallocate resources otherwise reserved for the performance of those Services, and/or (2) extend the timelines for completion of the Services under the relevant Work Order without liability or penalty
under this Agreement. Additional costs and adjusted timelines will be documented and provided in written form via a Change Order as described in Section 5.3(a). 
 (c) Process/Specifications Changes. Any change or modification to the Manufacturing Process or Specifications for any Product must be approved in advance by Portola, which approval shall not be
unreasonably withheld or delayed, and will be made in accordance with the change control provisions of the applicable Quality Agreement. All costs for implementing such changes and modifications will be [*]. 

  
 [*] = Certain
confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 8 

 5.4 Record and Sample Retention. 

(a) Records. Manufacturer will keep complete and accurate records (including without limitation reports, accounts, notes and
data) of all information and results obtained from performance of Services in form and substance as specified in the applicable Work Order, the applicable Quality Agreement and this Agreement (collectively, the “Records”). Subject
to the provisions of Section 9 and 10, all such Records will be the sole property of Portola and Manufacturer will not transfer, deliver or otherwise provide any such Records to any party other than Portola, without the prior written approval
of Portola. Records will be made reasonably available during normal business hours and with not less than ten (10) business days prior written notice for inspection, examination and copying by or on behalf of Portola. All original Records that
relate to the Development and Manufacture of Product under this Agreement will be retained and archived by Manufacturer at Portola’s expense in accordance with the Quality Agreement and Applicable Law, but in no case for less than a period of
[*] following completion of the applicable Work Order (the “Record Retention Period”). Upon Portola’s written request, Manufacturer will promptly provide Portola with copies of such Records at Portola’s expense. Upon expiration
of the applicable Record Retention Period applicable to any Records, the originals of such Records will be sent to Portola or Portola’s designee at Portola’s expense; provided, however, that Portola may elect to have such Records retained
in Manufacturer’s archives for an additional period of time at a reasonable charge to Portola by providing written notice to Manufacturer not less than ten (10) days prior to the expiration of the applicable Record Retention Period.
Manufacturer may retain one copy of such Records solely for the purposes of internal record-keeping, exercising its rights and monitoring its obligations under this Agreement and as required by Applicable Law. 

(b) Sample Retention. Manufacturer will take and retain, for such period and in such quantities as may be required by the Quality
Agreement and the applicable Work Order, samples of Product from the Manufacturing Process produced under this Agreement (the “Retained Samples”). Manufacturer will provide reasonable quantities of Product samples, other than the Retained
Samples, to Portola, upon Portola’s written request and at Portola’s expense. 
 5.5 Regulatory Matters.

 (a) Regulatory Approvals. Portola will be responsible for filing and/or obtaining, at its expense, all regulatory and
governmental approvals and permits necessary for Portola’s use of any Product Developed and/or Manufactured under this Agreement, including, without limitation, making IND submissions and any analogous submissions filed with the appropriate
Authority. Manufacturer will be responsible for providing to Portola, [*], supporting data and information relating to the Development and/or Manufacture of Product that is necessary for obtaining such approvals, requested in writing by the
applicable Authority and readily available to and in the possession or under the control of Manufacturer, including, without limitation, all Records, raw data, reports, authorizations, certificates, methodologies, Batch Documentation, raw material
specifications, SOPs, standard test methods, Certificates of Analysis, QA signed statements of compliance and other documentation relating to the Development and Manufacture of Product (or any component thereof). 

(b) Regulatory Inspections. Manufacturer will permit Portola or its Duly Authorized Representative(s) to be on site during an
inspection by an Authority being 

  
 [*] = Certain
confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 9 

 
conducted to ascertain the Facility or the Manufacturing Process compliance to cGMP for Portola’s API/Drug Substance US and Ex-US regulatory filing. The conduct of the inspection in so far
as it remains within the scope of Manufacturer’s responsibility will be the sole responsibility of the Manufacturer. Manufacturer will give as much advance notice as possible to Portola of any such visit or inspection. Manufacturer will provide
to Portola a copy of any report or other written communication received from such Authority in connection with such visit or inspection, and any written communication received from the Authority relating to the Product, the Facility (if it relates
to or affects the Development and/or Manufacture of Product) or the Manufacturing Process, within seventy-two (72) hours after receipt thereof, and will consult with, and Portola before responding to each such communication that shall attend to
the best interests of both parties and shall ensure Portola’s timely product approval. Manufacturer will provide Portola with a copy of its final responses within five (5) business days after submission thereof. 

(c) Notification of Regulatory Agencies and Regulatory Submissions. Portola shall be responsible for all communication with
Regulatory Agencies including notification of process/production changes and the submission of Annual Reports. 
 (d) Recall
of Product. Recall. The handling of field alerts, recalls and market withdrawals (collectively, “Recalls”) of all Product shall be within the sole discretion of Portola and Portola will notify Hovione promptly of any Recall of Product.
Notification to any Regulatory Authority and the conduct of such Recall shall be the sole responsibility of Portola. Hovione shall (a) cooperate fully with Portola in the event of any such Recall and (b) provide such assistance in
connection therewith as Portola may reasonably request. Portola shall bear all expenses of any Recall unless and to the extent such Recall directly results from Hovione’s negligence or willful misconduct, in which case Hovione shall
(i) bear the actual, documented and reasonable expenses of the parties in carrying out the Recall and (ii) use commercially reasonable efforts to replace the Product subject to such Recall with conforming Product as soon as reasonably
practicable at Hovione’s expense. In all events, [*] under this Section 5.5 for such Recall [*] to the [*] for such [*] applicable [*]. 
 5.6 Waste Disposal. The generation, collection, storage, handling, transportation, movement and release of hazardous materials and waste generated in connection with the Services will be the
responsibility of Manufacturer at Manufacturer’s sole cost and expense. Without limiting other applicable requirements, Manufacturer will prepare, execute and maintain, as the generator of waste, all licenses, registrations, approvals,
authorizations, notices, shipping documents and waste manifests required under Applicable Law. 
 5.7 Safety Procedures.
Portola is responsible for, and will provide Manufacturer with a copy of the most recent Safety Data for the API, Intermediates, Regulated Intermediates and related products contained within the manufacturing process. Portola will notify
Manufacturer in writing of any hazardous conditions or hazardous waste known to Portola that may exist or be produced by Manufacturer in the course of performing the Services contemplated by this Agreement. Portola will inform Manufacturer of any
new information related to the safety of the API, process or related products as soon as it becomes aware of any such information. Subject to the foregoing, Manufacturer will be solely responsible for implementing and maintaining health and safety
procedures for the performance of Services and 

  
 [*] = Certain
confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 10 

 
for the handling of any materials or hazardous waste used in or generated by the Services. Manufacturer, in consultation with Portola, will develop safety and handling procedures for API/Drug
Substance and Product; provided, however, that Portola will have no responsibility for Manufacturer’s health and safety program. In the event new safety information changes Manufacturer’s safety classification of the materials and requires
Manufacturer to implement new safety procedures and or equipment, such costs shall be [*]. 
 6. Testing and Acceptance
Process. 
 6.1 Testing by Manufacturer. The Product to be Manufactured under this Agreement will be Manufactured in
accordance with the Work Order, the Manufacturing Process approved by Portola and the Quality Agreement. Each Batch of Product will be sampled and tested by Manufacturer against the Specifications, and the quality assurance department of
Manufacturer will review the records relating to the Manufacture of the Batch and will assess if the Manufacture has taken place in compliance with the Quality Agreement and the Manufacturing Process. 

6.2 Provision of Records. If, based upon such tests, a Batch of Product conforms to the Specifications and was Manufactured
according to the Quality Agreement and the Manufacturing Process, then a Certificate of Analysis, which will include, if applicable, a QA signed statement of compliance, will be completed and approved by the quality assurance department of
Manufacturer. This Certificate of Analysis, the Specifications, and a complete and accurate copy of the Batch records (collectively, the “Batch Documentation”) for each Batch of Product will be delivered to Portola by a reputable
overnight courier or by registered or certified mail, postage prepaid, return receipt required to verify delivery date. Upon reasonable request, Manufacturer will also deliver to Portola, [*], copies of raw data, reports, authorizations,
certificates, methodologies, raw material specifications, standard test methods, and other documentation in the possession or under the control of Manufacturer relating solely to the Manufacture of each Batch of Product as agreed by the Parties in
the applicable Work Order. If Portola has not received all such Batch Documentation at the time of receipt of the Batch, Portola will notify Manufacturer in writing. If Portola requires additional copies of such Batch Documentation, these will be
provided by Manufacturer to Portola [*]. 
 6.3 Review of Batch Documentation; Acceptance. Portola will review the Batch
Documentation for each Batch of Product and may test samples of the Batch of Product against the Specifications. Portola will notify Manufacturer in writing of its acceptance or rejection of such Batch within four (4) weeks of receipt of the
Batch Documentation relating to such Batch; provided, that, if Portola does not provide Manufacturer with notice of rejection of a Batch on or before the expiration of such review period, Portola shall be deemed to have accepted such Batch. During
this review period, the parties agree to respond promptly, but in any event within ten (10) days, to any reasonable inquiry by the other party with respect to such Batch Documentation. Delays by Portola in reviewing of batch documentation do
not extend the obligation of payment period for the related invoices. Subject to Section 6.4, Portola has no obligation to accept a Batch if such Batch does not comply with the Specifications and/or was not Manufactured in compliance with the
Quality Agreement and the Manufacturing Process. 

  
 [*] = Certain
confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 11 

 6.4 Disputes. In case of any disagreement between the parties as to whether Product
conforms to the applicable Specifications or the Quality Agreement, the quality assurance representatives of the parties will attempt in good faith to resolve any such disagreement and Portola and Manufacturer will follow their respective SOPs to
determine the conformity of the Product to the Specifications and the Quality Agreement. If the foregoing discussions do not resolve the disagreement in a reasonable time (which will not exceed thirty (30) days), a representative sample
of such Product will be submitted to an independent testing laboratory mutually agreed upon by the parties for tests and final determination of whether such Product conforms with such Specifications. The laboratory must meet the Quality Agreement,
be of recognized standing in the industry, and consent to the appointment of such laboratory will not be unreasonably withheld or delayed by either party. Such laboratory will use the test methods contained in the applicable Specifications. The
determination of conformance by such laboratory with respect to all or part of such Product will be final and binding on the parties. The fees and expenses of the laboratory incurred in making such determination will be paid by the party against
whom the determination is made. 
 6.5 Product Non-Compliance and Remedies. If following the receipt of a notice of
rejection from Portola pursuant to Section 6.3, it is determined by agreement of the Parties (or in the absence of such agreement, by the laboratory) that a Batch of Product fails to conform to the Specifications or was not Manufactured in
compliance with the Quality Agreement and the Manufacturing Process, then Manufacturer will, [*]: 
 (a) refund in full the
fees and expenses paid by Portola for such Batch, including the costs of Portola Materials used in the Manufacture of such Batch; or 
 (b) at Manufacturer’s cost and expense, including the costs of Portola Materials used in the Manufacture of such Batch, produce a new Batch of Product as soon as reasonably possible; or 

(c) Rework or Reprocess the non-confirming Batch, at Manufacturer’s cost and expense, so that the Batch can be deemed to have been
Manufactured in compliance with the Quality Agreement and the Manufacturing Process, and to conform to Specifications. 
 Moreover, the parties
will meet to discuss, evaluate and analyze the reasons for and implications of the failure to comply with the Quality Agreement and/or the Manufacturing Process and will decide whether to proceed with or to amend the applicable Work Order, or to
terminate such Work Order. 
 6.6 Disposition of Non-Conforming Product. The ultimate disposition of non-conforming
Product will be the responsibility of Portola’s quality assurance department and [*]. 
 7. Shipping and Delivery.

 7.1 Shipping; Delivery. Manufacturer agrees, if so specified in the applicable Work Order, not to ship Product to
Portola or its designee until it has received a written approval to release and ship from Portola, which approval shall be provided by Portola no later than ten (10) days from the determination that such Product is conforming Product.
Manufacturer will 

  
 [*] = Certain
confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 12 

 
ensure that each Batch will be delivered to Portola’s designated carrier, (a) on the delivery date and to the destination designated by Portola in writing, and (b) in accordance
with the instructions for shipping and packaging specified by Portola in the applicable Work Order or as otherwise agreed to by the parties in writing. Delivery terms will be FCA the Facility (Incoterms 2000). 

8. Price and Payments. 
 8.1 Price. The price of Product and/or the fees for the performance of Services will be set forth in the applicable Work Order. 

8.2 Invoice. Unless otherwise agreed upon by the Parties, Manufacturer will invoice Portola according to the invoicing schedule in
the applicable Work Order. Payment of invoices will be due [*] after receipt of the invoice by Portola. 
 8.3 Payments.
Portola will make all payments pursuant to this Agreement by wire transfer to a bank account designated in writing by Manufacturer. All payments under this Agreement will be made in United States Dollars. 

8.4 Taxes. Duty, sales, use or excise taxes imposed by any governmental entity that apply to the provision of Services will be
borne by Portola (other than taxes based upon the income of Manufacturer). 
 9. Intellectual Property Rights. Except as
provided in this Section 9, ownership of Technology developed or discovered by either party alone or both together in the course of performance of this Agreement will follow inventorship as established in accordance with United States patent
laws. 
 9.1 Portola Technology. All rights to and interests in Portola Technology will remain solely in Portola and no
right or interest therein is transferred or granted to Manufacturer. Manufacturer acknowledges and agrees that it shall not acquire a license or any other right to Portola Technology except as provided in this Section 9.1. Portola hereby grants
Manufacturer a non-exclusive, fully paid license under the Portola Technology for the limited purpose of carrying out the Services under this Agreement; provided that, such limited, non-exclusive license will expire upon the completion of such
Services or the termination or expiration of this Agreement, whichever is the first to occur. 
 9.2 Manufacturer
Technology. All rights to and interests in Manufacturer Technology will remain solely in Manufacturer and no right or interest therein is transferred or granted to Portola. Portola acknowledges and agrees that it will not acquire a license or
any other right to Manufacturer Technology. 
 9.3 Improvements. Manufacturer agrees that all Improvements will be the
sole and exclusive property of Portola and are hereby assigned to Portola (or its designee) without additional compensation to Manufacturer. Manufacturer will take such steps as Portola may reasonably request (at Portola’s expense) to vest in
Portola (or its designee) ownership of the Improvements. 

  
 [*] = Certain
confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 13 

 9.4 Non-Exclusive License. Portola hereby grants to Manufacturer a non-exclusive,
[*], worldwide license, [*], to use Improvements that relate to Manufacturer Technology or the Confidential Information of Manufacturer, in the development and [*] that do not [*] or [*]. 

9.5 Patent Filings. Portola will have the exclusive right and option, but not the obligation, to prepare, file, prosecute,
maintain and defend at its sole expense, any patents that claim and/or cover the Improvements and will keep Manufacturer reasonably informed with regard thereto, including providing copies of all filings and material correspondence sent to or
received from applicable patent offices. In the event that Portola requests that manufacturer provides legal assistance for such filings Portola shall compensate Manufacturer for the work performed including any attorney’s fees associated with
writing or reviewing drafts of Patents. [*] if Portola [*] that [*] to be it’s [*] and prefers to [*] as a [*]. If Portola declines to file and prosecute any patent applications, or maintain any patents, relating to Improvements, it will give
Manufacturer reasonable notice to this effect and, thereafter, Manufacturer may, upon written notice to Portola, assume the exclusive right and option, but not the obligation, to file and prosecute such patent applications and/or maintain such
patents, in the name of Portola and at Manufacturer’s sole expense. Should Manufacture elect to file and prosecute such patent applications and/or maintain such patents in the name of Portola, Portola shall promptly (a) deliver to
Manufacturer copies of all necessary files related to the patent applications and/or patents with respect to which responsibility has been transferred and shall take all actions and execute all documents reasonably necessary for Manufacturer to
assume such responsibility, (b) [*] to Manufacturer any [*] then [*] and [*] and/or [*] by Portola (each, a “[*]”) and (c) [*] Manufacturer [*], with [*] the Improvements covered by such patent applications and/or patent(s) [*].
Unless otherwise authorized by Portola, Manufacturer shall not have the right to [*]. 
 10. Confidentiality. 

10.1 Definition. As used in this Agreement, “Confidential Information” means any scientific, technical, trade or
business information which is given by one party to the other and which is treated by the disclosing party as confidential or proprietary or is developed by one party for the other under the terms of this Agreement. The disclosing party will, to the
extent practical, use reasonable efforts to label or identify as confidential, at the time of disclosure all such Confidential Information that is disclosed in writing or other tangible form. Confidential Information of Manufacturer includes, but is
not limited to, Manufacturer Technology, whether or not labeled confidential. Confidential Information of Portola includes, but is not limited to, Portola Technology and Improvements, whether or not labeled confidential. 

10.2 Obligations. Each party agrees (a) to keep confidential the Confidential Information of the other party, (b) not to
disclose the other party’s Confidential Information to any third party without the prior written consent of such other party, and (c) to use such Confidential Information only as necessary to fulfill its obligations or in the reasonable
exercise of rights granted to it under this Agreement; provided, however, that the foregoing obligations shall not apply to Confidential Information that is (i) in possession of the receiving party at the time of disclosure, as
reasonably demonstrated by written records and without obligation of confidentiality, (ii) later becomes part of the public domain through no fault of the receiving 

  
 [*] = Certain
confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 14 

 
party, (iii) received by the receiving party from a third party without obligation of confidentiality, or (iv) developed independently by the receiving party without use of, reference
to, or reliance upon the disclosing party’s Confidential Information by individuals who did not have access to Confidential Information. Notwithstanding the foregoing, a party may disclose (y) Confidential Information of the other party to
its Affiliates, and to its and their directors, employees, consultants, and agents in each case who have a specific need to know such Confidential Information and who are bound by a like obligation of confidentiality and restriction on use, and
(z) Confidential Information of the other party to the extent such disclosure is required to comply with Applicable Law or to defend or prosecute litigation; provided, however, that the receiving party provides prior written
notice of such disclosure to the disclosing party and takes reasonable and lawful actions to avoid or minimize the degree of such disclosure. Moreover, Portola may disclose any Confidential Information of Manufacturer included in the Records and
relating to the Development and/or Manufacture of Product to entities with whom Portola has a marketing and/or development collaboration with respect to Product and that have a specific need to know such Confidential Information and that are bound
by a like obligation of confidentiality and restrictions on use. For the avoidance of doubt, Portola shall [*] provide to any Third Party [*]. 
 10.3 Public Statements. Except to the extent required by Applicable Law or the rules of the U.S. Securities and Exchange Commission, any stock exchange or NASDAQ, neither party will make any public
statements or releases concerning this Agreement or the transactions contemplated by this Agreement, or use the other party’s name in any form of advertising, promotion or publicity, without obtaining the prior written consent of the other
party, which consent will not be unreasonably withheld or delayed. 
 11. Representations and Warranties. 

11.1 Manufacturer’s Representations and Warranties. Manufacturer represents and warrants to Portola that: 

(a) it has the full power and right to enter into this Agreement and the execution, delivery and performance of this Agreement does not
breach, violate, contravene or constitute a default under any contracts, arrangements or commitments to which Manufacturer is a party or by which it is bound; 
 (b) the Services will be performed with requisite care, skill and diligence, in accordance with Applicable Law and industry standards, and by individuals who are appropriately trained and qualified;

 (c) to the best of its knowledge, the use of Manufacturer Technology in the performance of the Services will not infringe
the intellectual property rights of any third party and it will promptly notify Portola in writing should it become aware of any claims asserting such infringement; 
 (d) at the time of shipment of Product to Portola, such Product (i) will have been Manufactured in accordance with Applicable Law, the Manufacturing Process, the applicable Quality Agreement and
Specifications; and 
 (e) it has not been debarred, nor is it subject to a pending debarment, and that it will not use in any
capacity in connection with the Services any person who has been debarred pursuant to section 306 of the FDCA, 21 U.S.C. § 335a, or who is the subject of a conviction described in such section. Manufacturer agrees to notify Portola in writing
promptly if Manufacturer or any person who is performing Services is debarred or is the subject of a conviction described in section 306, or if any action, suit, claim, investigation, or proceeding is pending, or to the best of Manufacturer’s
knowledge, is threatened, relating to the debarment or conviction of Manufacturer or any person performing Services. 

  
 [*] = Certain
confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 15 

 11.2 Portola Representations and Warranties. Portola represents and warrants to
Manufacturer that: 
 (a) it has the full power and right to enter into this Agreement and that there are no outstanding
agreements, assignments, licenses, encumbrances or rights held by other parties, private or public, inconsistent with the provisions of this Agreement, and 
 (b) it will comply will all Applicable Law in its use of the Product and Deliverables, and 
 (c) to the best of its knowledge, the use of Portola Technology as contemplated in the Services and/or any Confidential Information of Portola and Portola Materials supplied by Portola pursuant to any
Work Order will not infringe the intellectual property rights of any third party and that it will promptly notify Manufacturer in writing should it become aware of any claims asserting such infringement. 

11.3 Disclaimer of Other Representations and Warranties. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES ANY
REPRESENTATIONS OR EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT. 

12. Indemnification. 
 12.1 Indemnification by Manufacturer. Manufacturer will indemnify, defend and hold harmless Portola, its Affiliates and their respective officers, directors, employees and agents (each a
“Portola Indemnitee”) from and against any and all losses, damages, liabilities or expenses (including reasonable attorneys fees and other costs of defense) (collectively, “Losses”) in connection with any and all
actions, suits, claims or demands that may be brought or instituted against any Portola Indemnitee by any third party based on, arising out of, or resulting from, any (a) material breach by Manufacturer of its representations, warranties or
covenants under this Agreement, or (b) grossly negligent act or omission or the willful misconduct of any Manufacturer Indemnitees in performing obligations under this Agreement, except in each case to the extent such losses are within the
scope of the indemnification obligation of Portola under Section 12.2 below. 

  
 [*] = Certain
confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 16 

 12.2 Indemnification by Portola. Portola will indemnify, defend and hold harmless
Manufacturer, its Affiliates and their respective officers, directors, employees and agents (each a “Manufacturer Indemnitee”) from and against any and all Losses in connection with any and all actions, suits, claims or demands that
may be brought or instituted against any Manufacturer Indemnitee by any third party based on, or arising out of, or resulting from (a) the use of the Product by Portola (including without limitation any claim of infringement of any patent or
trademark or the unauthorized use of a trade secret and any product liability claims), except to the extent that such Losses are within the scope of the indemnification obligation of Manufacturer under Section 12.1, (b) any material breach
by Portola of its representations, warranties or covenants under this Agreement, or (c) any grossly negligent act or omission or the willful misconduct of any Portola Indemnitees in performing obligations under this Agreement. 

12.3 Procedures. Each party agrees to notify the other party within thirty (30) days of receipt of any claims made for which
the other party might be liable under Section 12.1 or 12.2, as the case may be. Subject to Section 12.4, the indemnifying party will have the right to defend, negotiate, and settle such claims. The party seeking indemnification will
provide the indemnifying party with such information and assistance as the indemnifying party may reasonably request, at the expense of the indemnifying party. The parties understand that no insurance deductible will be credited against losses for
which a party is responsible under this Section 12. 
 12.4 Settlement. Neither party will be responsible or bound
by any settlement of any claim or suit made without its prior written consent; provided, however, that the indemnified party will not unreasonably withhold or delay such consent. If a settlement contains an absolute waiver of liability for the
indemnified party, and each party has acted in compliance with the requirements of Section 12.3, then the indemnified party’s consent will be deemed given. Notwithstanding the foregoing, Manufacturer will not agree to settle any claim on
such terms or conditions as would impair Portola’s ability or right to Manufacture, market, sell or otherwise use Product, or as would impair Manufacturer’s ability, right or obligation to perform its obligations under this Agreement.

 12.5 Limitation of Liability. NOTWITHSTANDING ANYTHING IN THIS AGREEMENT TO THE CONTRARY, IN NO EVENT WILL EITHER
PARTY BE LIABLE FOR ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR INDIRECT DAMAGES ARISING OUT OF THIS AGREEMENT, HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY. THIS LIMITATION WILL APPLY EVEN IF THE OTHER PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF
SUCH DAMAGE; PROVIDED, HOWEVER, THAT THIS LIMITATION WILL NOT APPLY TO DAMAGES RESULTING FROM BREACHES BY A PARTY OF ITS DUTY OF CONFIDENTIALITY AND NON-USE IMPOSED UNDER SECTION 10 OR ITS INDEMNIFICATION OBLIGATIONS UNDER THIS SECTION 12.
Notwithstanding anything to the contrary in this Section 12.5, the [*] of [*] under this Agreement (other than [*] arising under Section [*]) shall be [*] the [*] of [*] by [*] under this Agreement [*] to the [*] that [*]. 

  
 [*] = Certain
confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 17 

 13. Insurance. 

13.1 Manufacturer Insurance. Manufacturer will secure and maintain in full force and effect throughout the term of this Agreement
(and for at least five (5) years thereafter for claims made coverage), insurance with coverage and minimum policy limits set forth as follows: 
 (a) Worker’s Compensation, including coverage for occupational disease, with benefits determined by statute; 
 (b) Comprehensive General Liability and Personal/Advertising Injury, including coverage for contractual liability assumed by Manufacturer and coverage for Manufacturer’s independent
contractor(s), with per occurrence limits of at least one million dollars ($1,000,000) each and a general aggregate limit of two million dollars ($2,000,000); 
 (c) “All Risk” Property, valued at replacement cost, covering loss or damage to the Facility and Portola’s property and materials in the care, custody, and control of Manufacturer;
and 
 (d) Comprehensive Automobile Liability, Employer’s Liability, and Umbrella Liability, in such amounts and
under such terms as are customary for similar companies providing like services. 
 13.2 Evidence of Insurance.
Manufacturer will furnish to Portola a certificate from an insurance carrier (having a minimum AM Best rating of A describing the policy(s) in place. 
 13.3 Insurance Information. Manufacturer will comply, at Portola’s expense, with reasonable requests for information made by Portola’s insurance provider representative(s). 

14. Term and Termination. 
 14.1 Term. This Agreement will take effect as of the Effective Date and, unless earlier terminated pursuant to this Section 14, will expire on the later of (a) five (5) years from
the Effective Date, or (b) the completion of Services under the last Work Order executed by the parties prior to the fifth anniversary of the Effective Date. The term of this Agreement may be extended continuously for additional two
(2) year periods upon the agreement of the parties at least [*] prior to the expiration of the then current term. 
 14.2
Termination by Portola. Portola will have the right, in its sole discretion, to terminate this Agreement and/or any Work Order (a) upon sixty (60) days prior written notice to Manufacturer, or (b) immediately upon written notice if
(i) Manufacturer is, or provides written notice that it will be, unable to perform the Services in accordance with the agreed upon timeframe, if any, set forth in the applicable Work Order, or (ii) Manufacturer fails to obtain or maintain
any material governmental licenses or approvals required in connection with the Services. 
 14.3 Termination by Either
Party. Either party will have the right to terminate this Agreement or any signed Work Orders that are pending by giving sixty (60) days written notice to the other party, upon the occurrence of any of the following: 

(a) the other party files a petition in bankruptcy, or enters into an agreement with its creditors, or applies for or consents to the
appointment of a receiver or trustee, or makes an assignment for the benefit of creditors, or becomes subject to involuntary proceedings under any bankruptcy or insolvency law (which proceedings remain undismissed for sixty (60) days); 

  
 [*] = Certain
confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 18 

 (b) the other party fails to start and diligently pursue the cure of a material breach of
this Agreement within thirty (30) days after receiving written notice from the other party of such breach; or 
 (c) a force
majeure event that prevents performance (in whole or substantial part) of this Agreement or any pending Work Order for a period of at least [*]. In the case of a force majeure event relating to a pending Work Order, the right to terminate
will be limited to such Work Order. 
 (d) Either party concludes that the relationship established by this agreement has
become detrimental to its business and the party can demonstrate that it is in the best interest of both parties to terminate the agreement. 
 14.4 Effect of Termination. Manufacturer will, upon receipt of a termination notice from Portola, promptly cease performance of the applicable Services and will take all reasonable steps to
mitigate the out-of-pocket expenses incurred in connection therewith. In particular, Manufacturer will use commercially reasonable efforts to: 
 (a) immediately cancel, to the greatest extent possible, any third party or subcontractor obligations in effect with respect to any pending Work Order(s); 

(b) promptly inform Portola of any irrevocable commitments made in connection with any pending Work Order(s) prior to termination;

 (c) in the event that it is acceptable to the vendor, promptly return to the vendor for a refund all unused, unopened
materials in Manufacturer’s possession for which payment has been made by Portola that are related to any pending Work Order; provided that Portola will have the option, but not the obligation, to take possession of any such materials;

 (d) promptly inform Portola of the cost of any remaining unused, unreturnable materials ordered pursuant to any pending Work
Order(s), and either deliver such materials to Portola (or its designee) subject to the payment of such cost or properly dispose of them, as instructed by Portola and at Portola’s expense; and 

(e) perform only those services and activities mutually agreed upon by Portola and Manufacturer as being necessary or advisable in
connection with the close-out of any pending Work Order(s). 
 14.5 Return of Materials/Confidential Information. Upon
the expiration or termination of this Agreement, each party will promptly return all Confidential Information of the other party that it has received pursuant to this Agreement. Manufacturer will also promptly return all Portola Materials, retained
samples, data, reports and other property, information 

  
 [*] = Certain
confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 19 

 
and/or know-how in recorded form that was provided by Portola, or developed in the performance of the Services, that are owned by or licensed to Portola. Provided however, Manufacture may
(a) retain one copy of such Records solely for the purposes of internal record-keeping, exercising its rights and monitoring its obligations under this Agreement and as required by Applicable Law and (b) exclude or redact from such Records
any confidential or proprietary information of third parties or subcontractors. 
 14.6 Inventories. Upon expiration or
termination of this Agreement or a pending Work Order, Portola (a) will purchase from Manufacturer any existing inventories of Product conforming to the Specifications and Manufactured in accordance with the Quality Agreement and the
Manufacturing Process, at the price for such Product set forth in the applicable Work Order, and (b) may either (i) purchase any Product in process held by Manufacturer as of the date of the termination, at a price to be mutually agreed
(it being understood that such price will reflect, on a pro rata basis, work performed and non-cancelable out-of-pocket expenses actually incurred by Manufacturer with respect to the Manufacture of such in-process Product), or (ii) direct
Manufacturer to dispose of such material at Portola’s cost. 
 14.7 Payment Reconciliation. Within [*] after the
close-out of a Work Order, Manufacturer will provide to Portola a final invoice for that Work Order. If Portola has pre-paid to Manufacturer more than the amount in a final invoice then Manufacturer agrees to promptly refund that money to Portola,
or to credit the excess payment toward another existing or future Work Order, at the election of Portola. 
 14.8
Survival. Expiration or termination of this Agreement for any reason will not relieve either party of any obligation accruing prior to such expiration or termination or of any rights and obligations of the parties that by their terms survive
termination or expiration of this Agreement or of any Work Order, including, without limitation, the ownership (Section 9), the applicable confidentiality (Section 10), the representations and warranties (Section 11), indemnification (Section 12),
and provisions of this Agreement, and the provisions of the applicable Quality Agreement. 
 15. Miscellaneous.

 15.1 Independent Contractor. All Services will be rendered by Manufacturer as an independent contractor and this
Agreement does not create an employer-employee relationship between Portola and Manufacturer. Manufacturer will not in any way represent itself to be a partner or joint venturer of or with Portola. 

15.2 Force Majeure. Except as otherwise expressly set forth in this Agreement, neither party will have breached this
Agreement for failure or delay in fulfilling or performing any term of this Agreement when such failure or delay is caused by or results from causes beyond the reasonable control of the affected party, including, without limitation, fire, floods,
embargoes, shortages, epidemics, quarantines, war, acts of war (whether war be declared or not), insurrections, riots, civil commotion, strikes, terrorism, acts of God or acts, omissions, or delays in acting, by any governmental authority
(“force majeure”). The party affected by any event of force majeure will promptly notify the other party, explaining the nature, details and expected duration thereof. Such party will also notify the other party from
time to time as to 

  
 [*] = Certain
confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 20 

 
when the affected party reasonably expects to resume performance in whole or in part of its obligations under this Agreement, and to notify the other party of the cessation of any such event. A
party affected by an event of force majeure will use commercially reasonable efforts to remedy, remove, or mitigate such event and the effects thereof with all reasonable dispatch. If a party anticipates that an event of force majeure
may occur, such party will notify the other party of the nature, details and expected duration thereof. Upon termination of the event of force majeure, the performance of any suspended obligation or duty will promptly recommence. 

15.3 Notices. All notices must be written and sent to the address or facsimile number identified below or in a subsequent notice.
All notices must be given (a) by personal delivery, with receipt acknowledged, (b) by facsimile followed by hard copy delivered by the methods under (c) or (d), (c) by prepaid certified or registered mail, return receipt
requested, or (d) by prepaid recognized next business day delivery service. Notices will be effective upon receipt or at a later date stated in the notice. 
 If to Manufacturer, to: 
 Hovione Inter Limited 

40 Lake Drive 

East Windsor, NJ 08520 
 Attention: David Hoffman 
 Telephone: 609 918-2420 

Facsimile: 609 918-2615 
 And copy to: 
 Hovione FarmaCiencia SA 

Sete Casa, Loures 2670 
 Portugal 
 Attention: Guy Villax 

Telephone: +351 219 829 000 
 Telefax: +351 219 829 498 
 If to Portola, to: 

Portola Pharmaceuticals, Inc. 
 270 East Grand Avenue, Suite 22 
 South San Francisco, California 94080

 Attention: Joe Lambing 
 Telephone: 650-246-7300 
 Facsimile: 650-246-7776 

15.4 Assignment. This Agreement may not be assigned or otherwise transferred by either party without the prior written consent of
the other party; provided, however, that either party may, without such consent, but with notice to the other party, assign this Agreement, in whole or in part, (a) in connection with the transfer or sale of all or substantially
all of its assets or the line of business or product to which this Agreement relates, 

  
 [*] = Certain
confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 21 

 
(b) to a successor entity or acquirer in the event of a merger, consolidation or change of control, or (c) to any Affiliate. Any purported assignment in violation of the preceding sentence
will be void. Any permitted assignee will assume the rights and obligations of its assignor under this Agreement. 
 15.5
Entire Agreement. This Agreement, including the attached Appendices and any fully-signed Work Orders, each of which are incorporated herein, constitute the entire agreement between the parties with respect to the specific subject matter
hereof and all prior agreements with respect thereto are superseded. Each party hereto confirms that it is not relying on any representations or warranties of the other party except as specifically set forth herein. 

15.6 No Modification. This Agreement and and/or any Work Order or Quality Agreement may be changed only by a writing signed by
authorized representatives of both parties. 
 15.7 Severability; Reformation. Each provision in this Agreement is
independent and severable from the others, and no provision will be rendered unenforceable as a result of any other provision(s) being held to be invalid or unenforceable in whole or in part. If any provision of this Agreement is invalid,
unenforceable or too broad, that provision will be appropriately limited and reformed to the maximum extent permitted by applicable law 
 15.8 Governing Law. This Agreement will be construed and interpreted and its performance governed by the laws of the State of New York without regard to any choice of law principle that would
dictate the application of the law of another jurisdiction. Any action, suit or other legal proceeding which is commenced to resolve any matter arising under or relating to any provision of this Agreement will be commenced only in a court of the
State of California, U.S.A. and Portola and Manufacturer each consents to the jurisdiction of such a court. The application of the 1980 United Nations Convention on Contracts for the International Sale of Goods is hereby specifically excluded.

 15.9 Waiver. The waiver by either party hereto of any right under this Agreement or the failure to perform or of a
breach by the other party will not be deemed a waiver of any other right under this Agreement or of any other breach or failure by such other party whether of a similar nature or otherwise. 

15.10 Counterparts. This Agreement may be executed in any number of counterparts, each of which will be deemed an original and all
of which together will constitute one and the same instrument. 
 15.11 Headings. This Agreement contains headings only
for convenience and the headings do not constitute or form a part of this Agreement, and should not be used in the construction of this Agreement. 
 15.12 No Benefit to Third Parties. Except as set forth in Section 12 hereof, the representations, warranties, covenants and agreements set forth in this Agreement are for the sole benefit of
the parties hereto and their successors and permitted assigns, and they will not be construed as conferring any rights on any other persons. 

  
 [*] = Certain
confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 22 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their duly authorized
representatives as of the date first above written. 
  

									
	PORTOLA PHARMACEUTICALS, INC.	 		 	HOVIONE INTER LIMITED
					
	By	 	 /s/ Charles J. Homcy
	 		 	By	 	 /s/ G. Villax

					
	Print Name	 	 Charles J. Homcy, M.D.
	 		 	Print Name	 	 G. Villax

					
	Title	 	 President and Chief Executive Officer
	 		 	Title	 	 Chief Executive

					
	Date	 	 November 8, 2007
	 		 	Date	 	 26 October 2007

					
		 		 		 	By	 	 /s/ Douglas B. Hecker

					
		 		 		 	Print Name	 	 Douglas B. Hecker

					
		 		 		 	Title	 	 Manager – Sales & Marketing

					
		 		 		 	Date	 	 25 October 2007

  
 [*] = Certain
confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 23 

 APPENDIX A 
 SAMPLE WORK ORDER 
 THIS WORK ORDER is by and between Portola Pharmaceuticals, Inc.
(“Portola”) and Hovione Inter Limited (“Manufacturer”), and upon execution will be incorporated into the Development and Manufacturing Services Agreement between Portola and Manufacturer dated [EFFECTIVE DATE OF AGREEMENT]
(the “Agreement”). Capitalized terms in this Work Order will have the same meanings as set forth in the Agreement. 
 Portola hereby
engages Manufacturer to provide Services, as follows: 
  

	1.	API/Drug Substance. 

Describe the specific API/Drug Substance(s). 
  

	2.	Services. Manufacturer will render to Portola the following Services: 

 Describe the specific Services to be conducted by Manufacturer (summarize) or attach Manufacturer’s proposal. 
  

	3.	Facilit(ies). The Services described above will be rendered at the following facilities of Manufacturer: 

Include Facility address(es). 
  

	4.	Portola Materials. Portola will provide to Manufacturer the following materials to be used by Manufacturer to perform the Services: 

Describe specific materials being provided by Portola to Manufacturer. 

 

	5.	Portola Equipment. 

Include any equipment that will be provided by Portola to Manufacturer to be used by Manufacturer in performance of the Services.

  

	6.	Manufacturer Project Manager. Name and Title 

  

	7.	Portola Project Manager. Name and Title 

  

	8.	Compensation. The total compensation due Manufacturer for Services under this Work Order is INSERT WRITTEN AMOUNT (numerical amount). Such
compensation will be paid INSERT PAYMENT SCHEDULE OR REFERENCE PROPOSAL. Portola and Manufacturer must agree in advance of either party making any change in compensation. Manufacturer will invoice Portola to the attention of
INSERT NAME for Services rendered under this Agreement. Manufacturer will invoice Portola for all amounts due under this Work Order. All payments will be made by Portola within [*] of its receipt of an invoice.

  
 [*] = Certain
confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 24 

	9.	Records. Define records to be kept and provided to Portola. 

 

	10.	Quality Agreement. The provisions of the Quality Agreement, attached hereto as Attachment 1, are incorporated herein by reference.

 All other terms and conditions of the Agreement will apply to this Work Order. 

 

									
	WORK ORDER AGREED TO AND ACCEPTED BY:
			
	PORTOLA PHARMACEUTICALS, INC.	 		 	HOVIONE INTER LIMITED
					
	By	 	  
	 		 	By	 	  

					
	Print Name	 	  
	 		 	Print Name	 	  

					
	Title	 	  
	 		 	Title	 	  

					
	Date	 	  
	 		 	Date	 	  

  
 [*] = Certain
confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 25 

			
	SERVICE PROVIDER:	  	 • Hovione Inter Limited

	DMSA EFFECTIVE DATE:	  	 • January 17, 2007

  
  

AMENDMENT NO. 1 TO 
 DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT 
 THIS AMENDMENT NO. 1 (the
“Amendment”) to the Development and Manufacturing Services Agreement (defined below) is made effective as of January 17, 2012 by and between Portola Pharmaceuticals, Inc., (“Portola”) and Hovione Inter Limited (“Service
Provider”) and upon execution will be incorporated into the Development and Manufacturing Services Agreement between Portola and Service Provider dated January 17, 2007 (the “Development and Manufacturing Services Agreement”).
All capitalized terms not defined in this Amendment shall have the same meaning as in the Development and Manufacturing Services Agreement. 
 WHEREAS, a Development and Manufacturing Services Agreement, effective January 17, 2007, was entered into by and between Portola and Service Provider; and 

WHEREAS, the parties now wish to amend Section 14.1 of the Development and Manufacturing Services Agreement to extend the
term of the Agreement. 
 NOW, THEREFORE, in consideration of the premises contained herein and other valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto agree as follows: 
  

	 	1.	Term. Section 14.1 of the Development and Manufacturing Services Agreement is hereby deleted in its entirety and replaced with the following:

 This Agreement will take effect as of the Effective Data and, unless earlier terminated pursuant to this
Section 14, will expire on the later of (a) seven (7) years from the Effective Date, or (b) the completion of Services under the last Work Order executed by the parties prior to the fifth anniversary of the Effective Date. The
term of this Agreement may be extended continuously for additional two (2) year periods upon the agreement of the parties at least [*] prior to the expiration of the then current term. 
 Except as expressly provided in this Amendment, the Development and Manufacturing Services Agreement remains unchanged and in full force and effect. This Amendment may be executed in any number of
counterparts, each of which will be deemed an original and all of which together will constitute one and the same instrument. A facsimile or scanned copy of this Amendment that includes a party’s signature will be deemed an original.

 IN WITNESS WHEREOF, the parties have caused this Amendment to be executed by their duly authorized representatives as
of the Effective Date. 

  
 [*] = Certain
confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 Page 1 of 2

									
	PORTOLA PHARMACEUTICALS, INC.	 		 	HOVIONE INTER LIMITED
					
	By:	 	 /s/ Mardi C. Dier
	 		 	By:	 	 /s/ David Hoffman

					
	Print Name:	 	 Mardi C. Dier
	 		 	Print Name:	 	 David Hoffman

					
	Title:	 	 Chief Financial Officer
	 		 	Title:	 	 V. P. Exclusive

					
	Date:	 	 February 1, 2013
	 		 	Date:	 	 01 February 2013

  
 [*] = Certain
confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 Page 2 of 2Converted by EDGARwiz

RESCISSION AGREEMENT

This  RESCISSION AGREEMENT  (this  “Agreement”),  dated  as  of  April  8,  2013,  is  by  and

among  IGX GLOBAL INC., a  New  Jersey  corporation  (“IGX  NJ”),  THOMAS DUFFY,  (“Duffy”),

IGXGLOBAL  CORP.,  a  Delaware  corporation  (“IGX  DE”)  and   IGAMBIT  INC.,  a  Delaware

corporation  (“iGambit”).   IGX  NJ,  Duffy,  IGX  DE  and  iGambit  collectively  referred  to  herein

as “Parties” and each a “Party”.

WHEREAS, IGX NJ, Duffy,  IGX DE  and iGambit  are parties to  a certain  Asset  and  Stock

Purchase  Agreement  dated  as  of  December  28,  2012  (as  amended  and  in  effect,  the  “Purchase

Agreement”)  pursuant  to  which  (a)  IGX  DE  purchased  from  IGX  NJ  substantially  all  of  the

assets  of  IGX  NJ  (the  assets  so  purchased  being  the  “IGX  NJ  Assets”)  and  (b)  IGX  DE

purchased  from  Duffy  the  entire  issued  share  capital  of  IGXGlobal  UK  Limited  (“IGX  UK”),

being 1 ordinary share of £1.00 (the “IGX UK Shares”); and

WHEREAS,  pursuant  to  the  terms  and  conditions  of  this  Agreement,  the  Parties  desire  to

cancel,  rescind  and  render  null  and  void,  ab  initio,  the  Purchase  Agreement,  and  all  other

documents, instruments, securities and other certificates executed or delivered in connection with

the   transactions   described   by   the   Purchase   Agreement,   including   without   limitation   those

documents, instruments, securities  and other  certificates listed on  Schedule I  hereto (collectively

with the Purchase Agreement, the “Purchase Documents”);

NOW,  THEREFORE,  in  consideration  of  the  mutual  covenants  and  promises  set  forth

herein,  and  for  other  good  and  valuable  consideration,  the  receipt  and  sufficiency  of  which  are

hereby acknowledged, the Parties hereto, intending to be legally bound, hereby agree as follows:

1.

Rescission.    Effective  upon  the  Effective  Time  (as  defined  in  Section  2  below),  the

Parties shall, and effective upon the Effective  Time hereby do, (a) cancel  and rescind  each  of the

Purchase  Documents,  and  the  transactions  contemplated  therein,  and  (b)  declare  each  of  the

Purchase  Documents,  and  the  transaction  contemplated  therein,  null  and  void,  ab  initio  for  all

purposes,  including,   without   limitation,   tax   purposes   (collectively,   the   “Rescission”).     The

Parties  hereby  acknowledge  and  agree  that,  as  a  result  of  the  Rescission,  each  party  shall  be  in

the  same  position  it  was  in  in  immediately  prior  to  the  consummation  of  the  transactions

contemplated  by  the  Purchase  Documents,  in  every  respect  other  than  as  otherwise  expressly

contemplated by this Agreement.

2.

Effectiveness.   Subject to Section 6, the Rescission shall be effective at the time and date

(the  “Effective  Time”)  that  all  conditions  to  the  obligations  of  the  Parties  to  consummate  the

Rescission set forth in Sections 3(a) and (b) below have been satisfied or waived.

3.

Conditions.

(a)

Conditions to  Obligations of IGX NJ and Duffy.   All  obligations of IGX NJ and

Duffy  to  effect  the  Rescission  are  subject  to  the  fulfillment  (or  waiver  by  IGX  NJ  and  Duffy,

except as otherwise provided, and subject to, Section 3(c) below) of the following conditions:

652541

- 2 -

(i)

IGX  DE  and  iGambit  shall  have  performed  in  all  material  respects  all

obligations respectively required under this Agreement by them; and

(ii)

Each   of   IGX   DE   and   iGambit   shall   have   delivered   or   caused   to   be

delivered each of the following:

(A)

A  Certificate  of  the  Secretary  of  each  of  IGX  DE  and  iGambit

showing the signatures of those officers of IGX DE and iGambit, respectively, authorized to sign

on   behalf   of   IGX   DE   and   iGambit   this   Agreement   and   all   other   documents,   instruments,

securities   and   other   certificates   executed   or   delivered   in   connection   with   the   transactions

described  by  this  Agreement  (collectively  with  this  Agreement,  the  “Rescission  Documents”)

and certifying that  said  signatures  are  the  signatures  of  said authorized officers,  which  certificate

shall be delivered to IGX NJ and Duffy concurrently with the execution of this Agreement;

(B)

Resolutions  of  the  shareholders  (if  necessary)  and  the  directors  of

each  of  IGX  DE  and  iGambit  certified  by  the  Secretary  of  each  of  IGX  DE  and  iGambit  as

having  been  duly  and  validly  adopted  and  as  being  in  full  force  and  effect  on  the  date  hereof,

authorizing  the  execution  and  delivery  by  each  of  IGX  DE  and  iGambit  of  this  Agreement  and

other  Rescission  Documents,  and  authorizing  the  performance  by  IGX  DE  and  iGambit  of  the

transactions contemplated hereby and thereby, which certificate shall be delivered to IGX NJ and

Duffy concurrently with the execution of this Agreement;

(C)

For    avoidance    of    doubt,    notwithstanding   the    fact    that    the

transactions contemplated herein shall be a rescission of the Purchase Documents:

(1)

a  Bill  of  Sale  and  Assignment,  in  form  attached  hereto  as

Exhibit A, executed by IGX DE (the “Rescission Bill of Sale”);

(2)

an   Assignment   and   Assumption   Agreement,   in   form

attached   hereto   as   Exhibit   B,   executed   by  IGX   DE   (the   “Rescission   Assignment-

Assumption Agreement”); and

(3)

an  Assignment  and  Assumption  of  Lease,  in  form  attached

hereto  as  Exhibit  C,  executed  by  IGX  DE,  and  the  consent  of  the  landlord  under  such

applicable   lease   to   such   assignment   (the   “Rescission   Assignment-Assumption   of

Lease”); and

(D)

an  Assignment  and  Assumption  of  Employment  Agreement,  in

form   attached   hereto   as   Exhibit   D,   executed   by   iGambit,   pursuant   to   which   that   certain

Employment  Agreement  between  iGambit  and  Robin  Mayo  is  assigned  to  IGX  NJ  (the  “Mayo

Assignment-Assumption Agreement”); and

(E)

One or more share  certificates  representing the  IGX UK Shares  (or

an  appropriate  indemnity  if  such  certificate  has  been  lost)  for  cancellation  by  IGX  UK,  together

with  a  stock  transfer  form  in  respect  of  the  same  in  favor  of  IGX  NJ  executed  by  IGX  DE  (the

“IGX UK Share Transfer Documents”); and

652541

- 3 -

(iii)      IGX   NJ   and/or   Duffy   shall   have   secured   adequate   financing   (the

“Financing”)  in  an  aggregate  amount  equal  or  exceeding  the  sum  of:    (a)  the  Initial  iGambit

Payment  (as  defined  in  Section  3(b)(iii)  below);  (b)  the  amount  necessary  to  fully  repay  the

indebtedness  (the  “Keltic  Debt”)  of  iGambit  and  IGX  DE  to  Keltic  Financial  Partners  II,  LP

(“Keltic”)  under  the  Loan  and  Security  Agreement  dated  December  31,  2012  by  and  between

Keltic Financial Services  II LLP and IGXGLOBAL Corp. (collectively with all other documents,

instruments,  securities  and  other  certificates  executed  or  delivered  in  connection  with  the  Keltic

Debt,  the  “Keltic  Debt  Documents”);  (c)  any  outstanding  audit  fees  due  and  owing  from

iGambit  to  Fiondella,  Milone  &  LaSaracina  LLP  relating  to  IGX  NJ,  which  the  Parties  hereby

acknowledge to be $75,000.00 (the “Audit Fees”); (d) up to $95,000 of fees due and owing from

iGambit  to  Frontrunner  (the  “Frontrunner  Fees”);  and  (e)  up  to  $10,500  of  fees  due  and  owing

from iGambit to MK Appraisal Group for appraisal services (the “Appraisal Fees”); and

(iv)

A   payoff   letter   (the   “Keltic   Payoff   Letter”)   in   a   form   reasonably

acceptable  to  IGX  NJ  and  Duffy pursuant  to  which  (A)  Keltic  provides  amount  to  repay,  in  full,

the  Keltic  Debt  (and  per  diem),  and  (B)  upon  such  repayment,  (x)  all  Parties  shall  be  released

from  any  obligations  under  the  Keltic  Debt  Documents,  (y)  all  Keltic  Debt  Documents  shall  be

terminated  and  no  force  or  effect  and  (z)  any  and  all  liens,  encumbrances  and  security  interests

held  by  Keltic  against  any  IGX  NJ  Assets  or  IGX  UK  Shares  shall  be  terminated  and  released,

and all Parties shall be authorized to file such necessary UCC termination statements to effect the

same; and

(v)

iGambit  and/or  IGX  DE  shall  have  delivered  to  IGX  NJ  and  Duffy  true

and  accurate  copies  of  all  invoices  evidencing  the  Audit  Fees,  Frontrunner  Fees  and  Appraisal

Fees.

(b)

Conditions  to  Obligations  of  IGX DE  and  iGambit.   All  obligations  of  IGX  DE

and  iGambit  to  effect  the  Rescission  are  subject  to  the  fulfillment  (or  waiver  by  IGX  DE  and

iGambit,  except  as  otherwise  provided,  and  subject  to,  Section  3(c)  below)  of  the  following

conditions:

(i)

IGX   NJ   and   Duffy   shall   have   performed   in   all   material   respects   all

obligations respectively required under this Agreement by them; and

(ii)

Each  of  IGX  NJ  and  Duffy  shall  deliver  or  cause  to  be  delivered  each  of

the following:

(A)

A Certificate of the  Secretary of  IGX NJ  showing the signatures  of

those  officers  of  IGX  NJ  authorized  to  sign  on  behalf  of  IGX  NJ  this  Agreement  and  all  other

Rescission  Documents  and  certifying  that  said  signatures  are  the  signatures  of  said  authorized

officers,  which  certificate  shall  be  delivered  to  iGambit  concurrently  with  the  execution  of  this

Agreement;

652541

- 4 -

(B)

Resolutions  of  the  shareholders  (if  necessary)  and  the  directors  of

each  of  IGX  NJ  certified  by  the  Secretary  of  IGX  NJ  as  having  been  duly  and  validly  adopted

and as  being in full force  and effect on the date hereof, authorizing the execution and delivery by

each   of   IGX   NJ   of   this   Agreement  and   other   Rescission   Documents,   and   authorizing  the

performance  by  IGX  NJ  of  the  transactions  contemplated  hereby  and  thereby,  which  certificate

shall be delivered to iGambit concurrently with the execution of this Agreement;

(C)

For    avoidance    of    doubt,    notwithstanding   the    fact    that    the

transactions contemplated herein shall be a rescission of the Purchase Documents:

(1)

the      Rescission      Assignment-Assumption      Agreement,

executed by IGX NJ; and

(2)

the  Rescission  Assignment-Assumption  of  Lease,  executed

by   IGX   NJ,   and   the   consent   of   the   landlord   under   such   applicable   lease   to   such

assignment; and

(D)

the  Mayo  Assignment-Assumption  Agreement,  executed  by  IGX

NJ;

(E)

A  release  by  Keltic  of  IGX  DE  and  iGambit  from  any  obligations

and/or liabilities under the Keltic Debt Documents; and

(F)

Copies  of  all  Tax  Returns  (as  defined  by  the  Purchase  Agreement)

and evidence of tax  payments for the  period January 1, 2013 until  the Effective Time (as defined

in Section 2); and

(iii)      iGambit  shall  have  received  by  wire  transfer  to  a  designated  account  of

iGambit  the  sum  of  $275,000  (the  “Initial  iGambit  Payment”),  which  shall  be  paid  via  the

Deposit  (as  defined  in  Section  7)  and,  after  payment  of  the  Keltic  Debt  pursuant  to  Section

3(b)(v) below, Escrow Funds (as defined in Section 7); and

(iv)

IGX  NJ  and/or  Duffy  shall  have  remitted  payment  of,  or  iGambit  shall

have  received  written  releases  from  the  applicable  vendor  from  any  obligations  or  liabilities  for

(x)   the   Audit   Fees   to   Fiondella,   Milone   &   LaSaracina   LLP,   (y)   the   Frontrunner   Fees   to

Frontrunner,  and  (z)  the  Appraisal  Fees  to  MK  Appraisal  Group;  provided  that,  in  each  case,

IGX  DE  and/or  iGambit  shall  have  delivered  to  IGX  NJ  and  Duffy  true  and  accurate  copies  of

invoices for such fees from the applicable vendor, as contemplated by Section 3(a)(iv); and

(v)

IGX  NJ  and/or  Duffy  shall  have  remitted  payment  of  the  Keltic  Debt

pursuant to the terms of the Keltic Payoff Letter; and

(vi)

Duffy  shall  have  withdrawn  his  Notice  of  Default;  Reservation  of  Rights

to iGambit  dated  March  13, 2013 and Duffy shall receive no interest  installment payments under

the Promissory Note dated December 31, 2012 made  by iGambit  to Duffy until Rescission under

this Agreement is effective.

652541

- 5 -

(c)

Notwithstanding  any  contrary  provision  of  this  Agreement,  the  Parties  hereby

acknowledge  and  agree  that  the  effectiveness  of  the  Rescission  is  conditioned  upon,  and  the

Rescission shall not  occur, unless and  until:   (i) the  Keltic  Payoff Letter is  delivered to the Parties

pursuant  to  which  (A)  Keltic  provides  amount  to  repay,  in  full,  the  Keltic  Debt  (and  per  diem),

and  (B)  upon  such  repayment,  (x)  all  Parties  shall  be  released  from  any  obligations  under  the

Keltic  Debt  Documents  other  than  those  continuing  obligations  that  survive  termination  of  the

Keltic  Debt  Documents  as  provided  in  the  Keltic  Payoff  Letter,  (y)  all  Keltic  Debt  Documents

shall  be  terminated  and  no  force  or  effect  other  than  those  continuing  obligations  that  survive

termination  of the  Keltic  Debt  Documents  as  provided  in  the  Keltic  Payoff  Letter  and  (z) any and

all  liens,  encumbrances  and  security  interests  held  by  Keltic  against  any  IGX  NJ  Assets  or  IGX

UK  Shares  shall  be  terminated  and  released  other  than  those  liens  that  survive  termination  as

provided  in  the  Keltic  Payoff  Letter,  and  all  Parties  shall  be  authorized  to  file  such  necessary

UCC  termination  statements  to  effect  the  same;  and  (ii)  IGX  NJ  and/or  Duffy shall  have  remitted

payment  of  the  Keltic  Debt  in  full  pursuant  to  the  terms  of  the  Keltic  Payoff  Letter.    The

foregoing  conditions  may  not  be  waived  by  either  Party  without  the  prior  written  consent  of

Keltic.

4.

Additional Consideration.

(a)

As   additional   consideration   for  iGambit’s   agreement   to   effect   the  Rescission,

commencing upon  the  Rescission,  IGX  NJ  shall  pay  and  deliver  to  iGambit  the  sum  of  $350,000

(the “Consideration Balance”) in equal monthly installments of $19,444.44 (the “Installments”)

on  or  before  the  ten  (10th)  business  day  of  each  calendar  month  commencing  with  the  first  full

calendar month immediately following the Effective Time.

(b)

All  payments  hereunder  shall  be  made  by  check  to  iGambit  at  1050  W.  Jericho

Tpke.,  Suite  A,  Smithtown,  NY  11787,  or  by  wire  transfer  to  iGambit’s  bank  account(s),  such

bank  account  information  to  be  provided  to  IGX  NJ  by  iGambit.   Any  and  all  late  payments  of

Installments hereunder will  be subject to a late payment charge  from the date the amount  was due

until  paid  in  full  at  a  rate  per  annum  equal  to  the  of  lesser  of  six  percent  (6%)  per  annum  or  the

maximum  interest  rate  permitted  by  law  that  may  be  charged  under  these  circumstances.   In  the

event  of  default  in  the  payment  of  any  of  the  Installments  or  said  interest  when  due  as  herein

provided,  iGambit  may,  without  notice  or  demand,  declare  the  entire  Consideration  Balance  then

unpaid immediately due and payable.

5.

Covenants; Representations and Warranties.

(a)

Consents  and  Approvals.    Each  Party  shall  use  its  reasonable  best  efforts  to

obtain,  at  its own  expense,  those  authorizations,  consents, orders  and  approvals  of,  and  give  those

notices to and make all  filings with, all  governmental authorities and other persons that  may be or

become  necessary  or  advisable  for  the  performance  of  its  obligations  under  this  Agreement  and

the consummation of the  transactions contemplated hereby.   Each  Party shall  cooperate fully with

the  other  Parties  in  promptly  seeking  to  obtain  all  such  authorizations,  consents,  orders  and

approvals,  giving  such  notices,  and  making  such  filings,  including,  but  not  limited  to,  providing

all  such  information,  financial  or  otherwise,  reasonably  required  to  complete  filings  by  any  Party

652541

- 6 -

with  the  U.S.  Securities  and  Exchange  Commission,  the  Internal  Revenue  Service  and/or  other

governmental  regulators.   The  Parties  shall  not  take  any  action  that  is  reasonably  likely  to  have

the  effect  of  unreasonably  delaying,  impairing  or  impeding  the  receipt  of  any  such  required

authorizations, consents, orders or approvals.

(b)

Operation  of  Business.    From  the  date  hereof  through  the  Rescission,  IGX  DE

and  iGambit  covenant  and  agree  that  they  will:   (a)  use  their  commercially  reasonable  efforts  to

operate the business of IGX DE, IGX UK and the IGX NJ Assets (collectively, the “Business”) in

all material respects in the ordinary course consistent with past practice of IGX DE,  IGX UK and,

prior  to  the  Purchase  Documents,  IGX  NJ;  (b)  promptly  notify  IGX  NJ  and  Duffy,  in  writing,  of

any  material  development  with  respect  to  the  Business  or  any  of  the  IGX  NJ  Assets  or  IGX  UK

Shares; (c) not distribute, transfer, assign or sell any funds of IGX DE, IGX UK or the Business to

iGambit  or  any  other  person  without  the  prior  consent  of  Duffy;  and  (d)  Duffy,  as  President  of

IGX  DE,  will  promptly  notify  iGambit,  in  writing,  of  any  material  development  with  respect  to

IGX DE, the Business or any of the IGX NJ Assets or IGX UK Shares.

(c)

Inspection.   At  any  time  between  the  date  hereof  and  the  Rescission,  IGX  NJ  and

Duffy  shall  be  entitled,  through  its  employees  and  representatives,  to  enter  upon  and  make  such

reasonable  investigation  of  the  IGX  NJ  Assets,  IGX  UK  Shares  and  the  Business,  and  to  make

such  examination  of  the  books  and  records,  financial  condition  and  operations  of  the  IGX  NJ

Assets,  IGX  UK  Shares  and  the  Business  as  IGX  NJ  and/or  Duffy  may  reasonably  request,  and

IGX DE and iGambit will permit IGX NJ and Duffy to make copies thereof.

(d)

Publicity.    The  Parties  shall  cooperate  with  each  other  in  the  development  and

distribution   of   all   news   releases   and   other   public   disclosures   relating   to   the   transactions

contemplated by this Agreement.   None  of the Parties  shall  issue or make,  or allow to have issued

or  made,  any press  release,  public  announcement  or  public  disclosure  concerning the  transactions

contemplated   by  this   Agreement   without   the  advance   approval  in   writing  of   the   form   and

substance thereof by the other Parties.

(e)

Exclusivity.    From  and  after  the  date  of  this  Agreement  until  the  earlier  of  the

Rescission  or  the  termination  of  this  Agreement,  neither  IGX  DE  nor  iGambit  shall,  directly  or

indirectly,   through   any   of   their   respective   representatives   or   otherwise,   initiate,   solicit   or

encourage  (including  by  way  of  furnishing  non-public  information  or  assistance),  or  enter  into

negotiations  of  any  type,  directly  or  indirectly,  or  enter  into  a  confidentiality  agreement,  letter  of

intent or purchase agreement,  merger agreement  or other similar agreement with any person other

than  IGX  NJ  and/or  Duffy  with  respect  to  a  sale  of  all  or  any portion  of  the  IGX  NJ  Assets,  IGX

UK Shares  or Business, or a merger, consolidation, recapitalization, business combination, sale of

all  or  any  portion  of  IGX  DE  or  IGX  UK,  or  the  liquidation  or  similar  extraordinary  transaction

with respect IGX DE or IGX UK.

(f)

Confidentiality.   IGX  DE  and  iGambit  recognize  that  IGX NJ’s  business  interests

require  the  fullest  practical  protection  and  confidential  treatment  of  all  information  not  generally

known  within  the  relevant  trade  group  or  by  the  public,  including  all  documents,  writings,

memoranda,   business   plans,   illustrations,   designs,   plans,   processes,   programs,   inventions,

computer  software,  reports,  sources  of  supply,  customer  lists,  supplier  lists,  trade  secrets  and  all

652541

- 7 -

other  valuable  or  unique  information  and  techniques  acquired,  developed  or  used  by  any  of  IGX

DE,  IGX  UK  and/or  IGX  NJ  relating  to  their  businesses,  operations,  employees  and  customers

(hereinafter  collectively  termed  “Protected  Information”).    IGX  DE  and  iGambit  expressly

acknowledge   and   agree   that,   after   giving   effect   to   the   Rescission,   Protected   Information

constitutes   trade   secrets   and   confidential   and   proprietary   business   information   of   IGX   NJ.

Protected  Information  shall  not  include  information  which  is  or  becomes  part  of  the  public

domain  through  no  breach  of  this  Agreement  by  any  of  IGX  DE  or  iGambit.    IGX  DE  and

iGambit  acknowledge  that  Protected  Information  is  essential  to  the  success  of  Business,  and  it  is

the  policy  of  IGX  NJ  to  maintain  as  secret  and  confidential  Protected  Information,  which  gives

IGX  NJ  a  competitive  advantage  over  those  who  do  not  know  the  Protected  Information  and  is

expressly and implicitly protected by IGX NJ from unauthorized disclosure.  Accordingly, each of

IGX  DE  and  iGambit  agree,  and  agree  to  require  each  affiliate  controlled  by  IGX  DE  or  iGambit

(as  applicable),  to  hold  such  Protected  Information  in  a  fiduciary  capacity,  to  keep  secret  and  to

treat  confidentially  and  not  to,  and  not  to  permit  any  other  person  to,  directly  or  indirectly,

appropriate,  divulge, disclose or otherwise disseminate to any other  person  nor use in  any manner

for their, or any other person’s purposes or benefit any Protected Information, except to the extent

that  disclosure  is  required  by  law;  provided,  however,  that  IGX  DE  or  iGambit  (as  applicable)

shall  provide  IGX  NJ  with  notice  as  far  in  advance  of  any required  disclosure  as  is  practicable  in

order  for  IGX  NJ  to  obtain  an  order  or  other  assurance  that  any  information  required  to  be

disclosed  will  be  treated  as  Protected  Information  and  IGX  DE  or  iGambit  (as  applicable)  shall

use  all  reasonable  efforts  to  cooperate  with  IGX  NJ  in  connection  therewith  and  in  furtherance

thereof.   This  obligation  of  non-disclosure  of  information  shall  continue  to  exist  for  so  long  as

such information remains Protected Information.

(g)

No  Disparagement.   Each  Party  agrees  that  it  will  not  in  any  way  disparage  the

other  Party,  and/or  any  officer,  director,  agent,  representative,  employee,  parent,  subsidiary  or

other  affiliate  thereof,  or  make  or  solicit  any comments,  statements,  or  the  like  to  the  media  or  to

others  that  may  be  considered  to  be  derogatory  or  detrimental  to  the  good  name  or  business

reputation of any of the aforementioned parties or entities.

(h)

Taxes  and  Tax Returns.   For the  period January 1, 2013 until  the Effective Time,

as  pertains  to  the  operations  of  IGX  DE:   (i)  IGX  NJ  and/or  Duffy have  collected  and  remitted  to

the  appropriate  Governmental  Authority  (as  defined  by  the  Purchase  Agreement)  all  payroll,

quarterly  value  added  Tax  Returns,  sales  and  use  or  similar  Taxes  (as  defined  by  the  Purchase

Agreement)  required  to  have  been  collected,  including  any  interest  and  any  penalty,  addition  to

tax   or   additional   amount   unpaid,   and   has   been   furnished   properly   completed   exemption

certificates  for  all  exempt  transactions;  and  (ii)  IGX  NJ  and/or  Duffy  have  collected  and/or

remitted  to  the  appropriate  Governmental  Authority  all  property  Taxes,  customs  duties,  fees,  and

assessments  which  are  other  than  in  the  nature  of  income  taxes  or  charge  of  any  kind  whatsoever

(including  Taxes  assessed  to  real  property  and  water  and  sewer  rents  relating  thereto),  including

any interest  and  any penalty,  addition  to  tax  or additional  amount  unpaid.   Copies  of all  such  Tax

Returns  and  evidence  of  payments  for  the  period  January  1,  2013  until  the  Effective  Time  have

been given to iGambit.

652541

- 8 -

(i)

Discontinuance   of   IGX   DE.     Subsequent   to   the   Effective   Time,   and   upon

iGambit’s   receipt   of   all   applicable   Tax   Returns   pursuant   to   Section   5(h)   above,   iGambit

acknowledges  and  agrees  that  iGambit  shall  file  a  Certificate  of  Dissolution  of  IGX  Global  Corp.

with  the  Delaware  Secretary  of  State;  provided  that,  if  iGambit  does  not  file  such  Certificate  of

Dissolution  upon  the  Effective  Time,  it  shall  nonetheless  file,  upon  the  Effective  Time,  with  the

Delaware  Secretary  of  State  such  necessary  documents  to  change  the  corporate  name  of  IGX

Global  Corp.  to  a  name  which  does  not  include  “IGX”  or  “IGX  Global”  or  derivations  thereof.

Notwithstanding  the  foregoing,  iGambit  may  maintain  the  corporate  name  of  IGX  Global  Corp.

so long as it is required to maintain the  Lockbox under and as defined by the Keltic Payoff Letter,

provided  that  it  shall  not  use  “IGX”  or  “IGX  Global”  in  any  commercial  manner  other  than

maintaining such Lockbox.

(j)

Acknowledgment    of    Reimbursements.

IGX    DE    and    iGambit    hereby

acknowledge  and  agree  that,  previous  to  the  date  hereof,  IGX  DE  has  remitted  $130,000  in  cash

to  iGambit,  which  iGambit  shall  apply  as  reimbursements  for  the  expenses  listed  on  Schedule  II

hereto.

(k)

Financing.   IGX  NJ  and  Duffy  shall  use  their  best  efforts,  in  good  faith,  to  secure

Financing on or before April 30, 2013.  If by April 15, 2013, IGX NJ and Duffy have not received

reasonably  acceptable  terms  of  Financing  with  a  financing  partner,  IGX  NJ  and  Duffy  agree  that

IGX  DE  and  iGambit  may  commence  continuation  of  the  audit  and  appraisal  of  IGX  NJ  and  the

2013  audit  of  IGX  DE  in  anticipation  and  preparation  of  potential  SEC  filings  that  may  be

required should Rescission not occur;  provided, however, that  iGambit shall  be solely responsible

for  any  and  all  fees,  costs  and/or  expenses  thereafter  incurred  in  connection  with  such  audit  and

appraisal of IGX NJ and the 2013 audit of IGX DE.

(l)

Fees  and  Invoices.   iGambit  and/or  IGX  DE  hereby  represents  and  warrants  that

the  invoices  delivered  to  IGX  NJ  and  Duffy  as  contemplated  by  Section  3(a)(v)  are  true  and

accurate  copies  of  the  applicable  invoices  evidencing  the  Audit  Fees,  Frontrunner  Fees  and

Appraisal Fees.

(m)

Keltic  Debt.    Until  the  Effective  Time,  iGambit  shall  not  borrow  any  amounts

under,  nor  shall  it  amend  or  terminate  any  provisions  of,  the  Keltic  Debt  Documents.    The

foregoing  shall  not  prevent  IGX  DE  from  borrowing  funds  under  the  Keltic  Debt  Documents  in

the  ordinary  course  of  its  business,  provided  that  any  such  borrowing  shall  require  the  prior

approval of Duffy, whether as President of IGX DE or otherwise.

6.

Indemnifications; Releases.

(a)

Indemnification  of  IGX  DE  and  iGambit.   IGX  NJ  and  Duffy  hereby  covenant

and  agree  to  jointly  and  severally  indemnify  and  hold  harmless  IGX  DE  and  iGambit,  and  their

respective  successors  and  assigns,  at  all  times  from  and  after  the  Effective  Time,  against  and  in

respect  of  any and all demands, Claims (as defined by the Purchase Agreement),  causes of action,

administrative  orders  and  notices,  losses,  costs,  fines,  liabilities,  penalties,  interest,  damages  and

expenses  (including, without limitation, reasonable attorney fees and  expenses), resulting from, in

connection with or arising out of any:

652541

- 9 -

(i)

damage   or   loss   resulting   from   (A)   any   misrepresentation,   breach   of

warranty  or  breach  or  non-fulfillment  of  covenant  on  the  part  of  IGX  NJ  or  Duffy under  (x)  this

Agreement,  including,  but  not  limited  to,  IGX  NJ’s  and  Duffy’s  covenants  and  representations

regarding  the  Taxes  and  Tax  Returns  as  set  forth  in  Section  5(h)  (entitled  “Taxes  and  Tax

Returns”), or (y)  any other  Rescission  Document,  or (B)  any inaccuracy or  misrepresentation  in

or omission from any certificate or other  instrument  or document furnished  or to  be  furnished  by

or on behalf of IGX NJ or Duffy at the Effective Time, or (C) any of IGX NJ or Duffy (or any of

their  respective  officers,  directors  or  shareholders)  asserts  any  Claim  against  any  of  iGambit  or

IGX  DE  (or  any  of  its  affiliates,  representatives,  officers,  directors  or  shareholders)  that  arises

from any Released Claims (as defined in Section 6(c)(iii)); and

(ii)

all  Claims,  assessments,  judgments,  costs,  reasonable  attorneys’  fees  and

expenses  of  any  nature  incident  to  any  liability  for  sales  Taxes  (x)  owing  from  IGX  NJ  at  any

time  and/or  (y)  resulting  from  operations  of  IGX  DE  during  the  period  commencing  upon  the

Closing (as defined in the Purchase Agreement) and expiring at the Effective Time; and

(iii)      Claims,   assessments,   judgments,   costs,   reasonable   attorneys’   fees   and

expenses of any nature incident to any of the matters indemnified against pursuant to this Section

6(a), including,  without  limitation, all  such  costs  and  expenses  incurred  in  the  defense  thereof  or

in the enforcement by IGX DE and/or iGambit of any rights hereunder.

(b)

Indemnification  of  IGX  NJ  and  Duffy.   IGX  DE  and  iGambit  hereby  covenant

and  agree  to  jointly  and  severally  indemnify  and  hold  harmless  IGX  NJ  and  Duffy,  and  their

respective  successors,  heirs  and  assigns,  at  all  times  from  and  after  the  Effective  Time,  against

and in respect of any and all demands, Claims, causes of action, administrative orders and notices,

losses,   costs,   fines,   liabilities,   penalties,   interest,   damages   and   expenses   (including,   without

limitation,  reasonable  attorney  fees  and  expenses),  resulting  from,  in  connection  with  or  arising

out of any:

(i)

damage   or   loss   resulting   from   (A)   any   misrepresentation,   breach   of

warranty  or  breach  or  non-fulfillment  of  covenant  on  the  part  of  IGX  DE  or  iGambit  under  (x)

this    Agreement,    or    (y)    any    other    Rescission    Document,    or    (B)    any    inaccuracy    or

misrepresentation  in  or  omission  from  any  certificate  or  other  instrument  or  document  furnished

or  to  be  furnished  by  or  on  behalf  of  IGX  DE  or  iGambit  at  the  Effective  Time,  or  (C)  any  of

IGX  DE  or  iGambit  (or  any  of  their  respective  officers,  directors  or  shareholders)  asserts  any

Claim against  any of Duffy or  IGX NJ  (or  any of its  affiliates, representatives,  officers, directors

or shareholders) that arises from any Released Claims (as defined in Section 6(c)(iii)); and

(ii)

all  Claims,  assessments,  judgments,  costs,  reasonable  attorneys’  fees  and

expenses  of  any  nature  incident  to  any  liability  for  sales  Taxes  (x)  owing  from  iGambit  at  any

time  and/or  (y)  resulting  from  operations  of  IGX  DE  at  any  time  prior  to  the  Closing  or  at  any

time after the Effective Time; and

652541

- 10 -

(iii)      Claims,   assessments,   judgments,   costs,   reasonable   attorneys’   fees   and

expenses of any nature incident to any of the matters indemnified against pursuant to this Section

6(b), including,  without  limitation,  all  such  costs  and  expenses  incurred  in  the  defense  thereof or

in the enforcement by IGX NJ and/or Duffy of any rights hereunder.

(c)

Mutual Releases.

(i)

Except   with   respect   to   the   obligations   set   forth   in   this   Agreement

(including without limitation the indemnification obligations of Duffy and IGX NJ under Section

6(a)),  and  effective  upon  the  Effective  Time,  IGX  DE  and  iGambit  hereby  fully  and  forever

releases any and all claims, demands, actions, suits, obligations, debts, sums  of money, accounts,

covenants,   controversies,   agreements,   promises,   damages,   judgments,   breaches   of   contract,

breaches  of  duty,  acts,  omissions,  misfeasance,  malfeasance,  costs,  losses  and  expenses  of  every

type,  kind,  nature,  description  or  character,  of  any  jurisdiction,  foreign  or  domestic,  known  or

unknown,  whether  vicarious,  derivative,  or  direct,  that  IGX  DE  or  iGambit  ever  had,  may  now

have,  or  hereafter  have  or  may  have,  in  law  or  equity,  against  Duffy  or  IGX  NJ,  and/or  any

officer,  director,  agent,  representative,  employee,  parent,  subsidiary  or  other  affiliate  thereof,

relating  to,  or  arising  out  of,  the  Rescission,  or  the  operation  of  IGX  DE  from  the  Closing  (as

defined in the Purchase Agreement) until the Effective Time.

(ii)

Except   with   respect   to   the   obligations   set   forth   in   this   Agreement

(including  without  limitation  the  indemnification  obligations  of  iGambit  and  IGX  DE  under

Section 6(b)), and effective upon the Effective Time, IGX NJ  and Duffy hereby fully and forever

releases any and all claims, demands, actions, suits, obligations, debts, sums  of money, accounts,

covenants,   controversies,   agreements,   promises,   damages,   judgments,   breaches   of   contract,

breaches  of  duty,  acts,  omissions,  misfeasance,  malfeasance,  costs,  losses  and  expenses  of  every

type,  kind,  nature,  description  or  character,  of  any  jurisdiction,  foreign  or  domestic,  known  or

unknown,  whether  vicarious,  derivative,  or  direct,  that  IGX  NJ  or  Duffy  ever  had,  may  now

have,  or  hereafter  have  or  may  have,  in  law  or  equity,  against  iGambit  or  IGX  DE,  and/or  any

officer,  director,  agent,  representative,  employee,  parent,  subsidiary  or  other  affiliate  thereof,

relating  to,  or  arising  out  of,  the  Rescission,  or  the  operation  of  IGX  DE  prior  to  the  Closing  or

after the Effective Time.

(iii)      Each  of  the  Parties  covenants  not  to  bring  any  Claim,  which  is  released

pursuant  to  Section  6(c)(i)  or  (ii)  above  (a  “Released  Claim”)  against  any  released  Party  in  any

capacity  before  any  court,  arbitrator  or  other  tribunal  in  any  jurisdiction,  whether  as  a  claim,  a

cross-claim  or  counterclaim.   Any  Party  released  as  provided  in  this  Section  6(c)  may plead  this

Agreement as a complete bar to any Released Claim brought in derogation of this covenant not to sue.

7.

Methods of Termination.

(a)

This  Agreement  may  be  terminated  and  the  transactions  contemplated  hereby  may

be abandoned at any time prior to the Rescission:

(i)

by mutual written consent of the Parties;

652541

- 11 -

(ii)

by  any  Party,  if  a  governmental  authority  shall  have  issued  an  order,

decree  or  ruling  or  taken  any  other  action,  in  each  case  permanently  restraining,  enjoining  or

otherwise  prohibiting  the  transactions  contemplated  by  this  Agreement,  and  such  order,  decree,

ruling or other action shall have become final and nonappealable;

(iii)      by IGX NJ or  Duffy,  at any time  when iGambit or  IGX  DE is in breach of

any  of  its  covenants  pursuant  to  this  Agreement;  provided  that  such  breach  shall  not  have  been

cured, in the case of a covenant, within ten (10) business days following receipt by the  breaching

party of notice of such breach;

(iv)

by IGX DE or iGambit,  at any time when Duffy or  IGX NJ is in breach of

any  of  its  covenants  pursuant  to  this  Agreement;  provided  that  such  breach  shall  not  have  been

cured, in the case of a covenant, within ten (10) business days following receipt by the  breaching

party of notice of such breach; or

(v)

by  any  Party,  if  the  Rescission  has  not  occurred  on  or  before  April  30,

2013;  provided, however,  that  the  right  to  terminate this  Agreement  shall  not  be  available  to  any

Party  whose  breach  of  this  Agreement  has  been  the  cause  of,  or  resulted  in,  the  failure  of  the

Rescission to occur on or before such date.

(b)

In  the  event  of  termination  of  this  Agreement,  this  Agreement  shall  immediately

become  void  and  there  shall  be  no  liability hereunder  on  the  part  of  any Party  except  this  Section

7(b) and Sections 6, 8 and 9 shall remain in full force and effect.

(c)

Nothing  contained  in  this  Agreement  shall  relieve  any  Party  hereto  from  any

liability for any fraud or any breach of any covenant contained herein, and the rights of the Parties

to  pursue  all  remedies  for  any  such  fraud  or  breach  will  survive  such  termination  unimpaired.

Each Party’s right of termination under this Section 7 is in addition to any other rights it may have

under  this  Agreement  or  otherwise,  and  the  exercise  of  a  right  of  termination  will  not  be  an

election of remedies.

8.

Deposit;  Escrow.   Concurrently  with  the  execution  of  this  Agreement:   (a)  each  of  IGX

NJ,  Duffy,  iGambit  and  Roetzel  &  Andress  (the  “Escrow  Agent”)  shall  have  entered  into  an

Escrow  Agreement,  in  the  form  attached  hereto  as  Exhibit  E  (the  “Escrow  Agreement”);  and

(b) each  of  IGX  NJ,  Duffy,  IGX  DE and  iGambit  (as  applicable)  shall  execute and  deliver to  the

Escrow   Agent   to   hold   in   escrow   pursuant   to   the   terms   of   the   Escrow   Agreement   (i)   the

Rescission   Bill   of   Sale,   (ii)   the   Rescission   Assignment-Assumption   Agreement,   (iii)   the

Rescission    Assignment-Assumption    of    Lease,    (iv)    the    Mayo    Assignment-Assumption

Agreement   and   (v)   the   IGX   UK   Share   Transfer   Documents   (collectively,   the   “Escrowed

Documents”).    Furthermore,  on  or  before  April  2,  2013,  IGX  NJ  and/or  Duffy  shall  have

delivered:   (x)  to  the  Escrow  Agent  a  dollar  amount  equal  to  $200,000  (i.e.  the  Initial  iGambit

Payment  less the Deposit) to be held in escrow by the  Escrow Agent  pursuant  to the terms of the

Escrow  Agreement  (the  “Escrow  Funds”);  and  (y)  to  iGambit  $75,000  as  a  good  faith,  non-

refundable  deposit  (the  “Deposit”)  which  shall  be  credited  against  the  Initial  iGambit  Payment

due  and  owing  from  IGX  NJ  and  Duffy  upon  Rescission.  The  Escrow  Agreement  shall  provide

the  release  of the  Escrowed  Documents  to  IGX NJ  and  Duffy,  and  the  Escrow  Funds  to  iGambit

652541

- 12 -

as   payment   of   the   Initial   iGambit   Payment,   upon   written   notice   from   any   Party   that   the

conditions  for  Rescission  have  been  met  pursuant  to  this  Agreement.   Upon  termination  of  this

Agreement  pursuant  to  Section  6,  the  Escrowed  Documents  shall  be  returned  to  iGambit  and  be

deemed  void  and  of  no  force  or  effect,  and  the  Escrow  Funds  and  Deposit  shall  be  returned  to

IGX NJ or Duffy.

9.

Miscellaneous.

(a)

Mutual  Construction.   The  Parties  hereby  mutually  acknowledge  and  represent

that   they   have   been   fully   advised   by   their   respective   legal   counsel   of   their   rights   and

responsibilities  under  this  Agreement,  that  they  have  read,  know  and  understand  completely  the

contents  hereof,  and  that  they  have  voluntarily  executed  the  same.    The  Parties  further  hereby

mutually acknowledge that they have had input  into the drafting of this Agreement  and, therefore,

this Agreement  shall not  be construed  for  or  against  any Party, but  rather shall be  given  a fair  and

reasonable  interpretation,  based  on  the  plain  language  of  the  Agreement  and  the  expressed  intent

of the Parties.

(b)

Entire   Agreement.      This   Agreement   constitutes   the   entire   agreement   and

understanding   between   the   Parties   relating   to   the   subject   matter   contained   herein,   and   this

Agreement  may  not  be  altered,  amended  or  modified  in  any  respect  whatsoever,  except  by  a

writing duly executed by each of the Parties.

(c)

Further   Assurances.     The   Parties   agree   to   execute   and   deliver   such   other

agreements,   documents   or   instruments,   and   to   take   such   other   action,   as   may   reasonably

necessary  or  desirable  for  the  implementation  of  this  Agreement  and  the  consummation  of  the

transactions  hereby contemplated.   Notwithstanding the  above, in the  event  that  the Parties do not

receive the  full benefits  of this Agreement  as  a result of a  government  agency or  regulatory board

decision,  the  Parties  will  use  their  commercially  best  efforts  to  cause  all  of  the  IGX  DE  assets  to

be  transferred  and  assigned  to  IGX  NJ  and  Duffy,  and  all  related  expenses  shall  be  borne  equally

by the Parties.

(d)

Counterparts;   Electronic   Signatures.     This   Agreement   may  be   executed   in

several  counterparts,  each  of  which  shall  be  an  original,  so  that  all  of  which  taken  together  shall

constitute  one  and  the  same  instrument.    This  Agreement  may  also  be  executed  and  delivered

through  counterpart  signature  pages  transmitted  by  facsimile,  e-mail  or  other  electronic  means  or

media.

(e)

Governing  Law.    This  Agreement  shall  be  interpreted  under,  and  construed  in

accordance with, the laws of the State of Connecticut.

(f)

Rules  of  Usage.    In  this  Agreement,  unless  a  clear  intention  appears  otherwise:

(i) the  singular  number  includes  the  plural  number  and  vice  versa;  (ii) reference  to  any  person

includes  such  person’s  successors  and  assigns  but,  if  applicable,  only  if  such  successors  and

assigns  are  not  prohibited  by  this  Agreement,  and  reference  to  a  person  in  a  particular  capacity

excludes  such  person  in  any  other  capacity  or  individually;  (iii) reference  to  any  gender  includes

each   other   gender;   (iv) reference   to   any   agreement,   document   or   instrument   means   such

652541

- 13 -

agreement,  document  or  instrument  as  amended  or  modified  and  in  effect  from  time  to  time  in

accordance   with   the   terms   thereof;   (v) reference   to   any   law   means   such   law   as   amended,

modified,  codified,  replaced  or  reenacted,  in  whole  or  in  part,  and  in  effect  from  time  to  time,

including  rules  and  regulations  promulgated  thereunder;  (vi) “hereunder,”  “hereof,”  “hereto”  and

words  of  similar  import  shall  be  deemed  references  to  this  Agreement  as  a  whole  and  not  to  any

particular  section   or   other   provision   hereof;  (vii) “including”   (and   with   correlative   meaning

“include”)  means  including  without  limiting  the  generality  of  any  description  preceding  such

term; (viii) “or” is used in the inclusive sense of “and/or”; (ix) with respect to the determination of

any  period  of  time,  “from”  means  “from  and  including”  and  “to”  means  “to  but  excluding”;

(x) references  to  documents,  instruments  or  agreements  shall  be  deemed  to  refer  as  well  to  all

addenda,  schedules  or  amendments  thereto;  (xi) section  references  shall  be  deemed  to  refer  to  all

subsections thereof, unless otherwise expressly indicated; and (xii) “person” means any individual

or  any  corporation,  limited  liability  company,  association,  partnership,  limited  partnership,  trust

or estate, or government (or any agency or political subdivision thereof), or other business or legal

entity.

(g)

Attorney  Fees.    In  the  event  either  party  retains  the  services  of  an  attorney  or

attorneys  to  enforce  the  terms  of this  Agreement  or to  file  or defend  any action  arising out  of  this

Agreement, then the  prevailing party in any such  action shall  be  entitled to recover from the  other

party its  reasonable  fees  for attorneys,  plus  such  court  costs  and  expenses  as  may be  fixed  by any

court of competent jurisdiction.

[Intentionally Left Blank – Signature Page Follows]

652541

[Signature Page to Rescission Agreement]

IN  WITNESS  WHEREOF,  and  in   agreement   herewith,  the   Parties  have   executed   and

delivered this Agreement as of the date set forth in the preamble hereof.

IGX GLOBAL INC.

By:________________________

Name:

Title:

________________________

Thomas Duffy

IGXGLOBAL CORP.

By:________________________

Name:

Title:

IGAMBIT INC.

By:________________________

Name:

Title:

652541

Schedule I

     Employment Agreement dated as of January 1, 2013 between IGX DE and Duffy

     $1,000,000 Promissory Note dated December 28, 2012 issued by IGX DE  to IGX NJ and

Duffy, and guaranteed by iGambit

     Bill  of  Sale  and  Assignment  dated  as  of  December  28,  2012  between  IGX  NJ  and  IGX

DE

     Assignment and Assumption Agreement dated as  of December 28, 2012 between IGX NJ

and IGX DE

     Assignment  and  Assumption  of  Lease  dated  as  of  December  28,  2012  among  IGX  NJ,

IGX DE and Duffy

     Assignment  and  Assumption  of  Lease  dated  as  of  December  28,  2012  among  IGX  UK,

IGX DE and Duffy

652541

Schedule II



$60,000 paid to Keltic  Financial  Services for  Work Fee ($35,000) and Good Faith

Deposit ($25,000)



$25,000 paid to Frontrunner Consulting



$10,000 paid to MK appraisers for Valuation



$29,146  for  Robin  Mayo  payroll  and  expenses  ($17,182.76  net  pay,  $10,169.89

applicable payroll taxes, $1793.35 expense reimbursement)



$10,000 FML (Towards IGX DE portion of YE 2012 Audit Fees for 10K filing)

652541

Exhibit A

Form of Bill of Sale and Assignment

652541

Exhibit B

Form of Assignment and Assumption Agreement

652541

Exhibit C

Form of Assignment and Assumption of Lease

652541

Exhibit D

Form of Assignment and Assumption of Employment Agreement

652541

Exhibit E

Form of Escrow Agreement

652541

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00215-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00215-of-00352.parquet"}]]